BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 59.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhang KD, Hu B, Cen G, Yang YH, Chen WW, Guo ZY, Wang XF, Zhao Q, Qiu ZJ. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. World J Gastroenterol 2020; 26(19): 2349-2373 [PMID: 32476798 DOI: 10.3748/wjg.v26.i19.2349] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, Chen X, Qin C, Zhu Z, Wakefield MR, Nicholl MB. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol 2017;34:23. [PMID: 28058630 DOI: 10.1007/s12032-016-0880-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
3 Park JH, Jung KH, Kim SJ, Fang Z, Yan HH, Son MK, Kim J, Kang YW, Lee JE, Han B, Lim JH, Hong SS. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget 2017;8:112893-906. [PMID: 29348875 DOI: 10.18632/oncotarget.22850] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
4 Parker G, Brotchie H. Pancreatic Cancer and Depression: A Narrative Review. J Nerv Ment Dis 2017;205:487-90. [PMID: 28557883 DOI: 10.1097/NMD.0000000000000593] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
5 Zheng J, Hernandez JM, Doussot A, Bojmar L, Zambirinis CP, Costa-Silva B, van Beek EJAH, Mark MT, Molina H, Askan G, Basturk O, Gonen M, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Lyden D, Jarnagin WR. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. HPB (Oxford) 2018;20:597-604. [PMID: 29339034 DOI: 10.1016/j.hpb.2017.12.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
6 Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W, Wang X, Yang P. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br J Cancer. 2017;117:1846-1854. [PMID: 29123261 DOI: 10.1038/bjc.2017.365] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
7 Chen Q, Wang J, Zhang Q, Zhang J, Lou Y, Yang J, Chen Y, Wei T, Zhang J, Fu Q, Ye M, Zhang X, Dang X, Liang T, Bai X. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Br J Cancer. 2019;121:786-795. [PMID: 31588122 DOI: 10.1038/s41416-019-0595-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
8 Kumar V, Mondal G, Slavik P, Rachagani S, Batra SK, Mahato RI. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Mol Pharm. 2015;12:1289-1298. [PMID: 25679326 DOI: 10.1021/mp500847s] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 9.2] [Reference Citation Analysis]
9 Mehta S, Tan GI, Nahm CB, Chua TC, Pearson A, Gill AJ, Samra JS, Mittal A. Pancreatic resection in patients with synchronous extra-pancreatic malignancy: outcomes and complications. ANZ J Surg 2020;90:290-4. [PMID: 31943690 DOI: 10.1111/ans.15651] [Reference Citation Analysis]
10 Ding L, Liou GY, Schmitt DM, Storz P, Zhang JS, Billadeau DD. Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia. J Pathol 2017;243:65-77. [PMID: 28639695 DOI: 10.1002/path.4928] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
11 Ji L, Gong C, Ge L, Song L, Chen F, Jin C, Zhu H, Zhou G. Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma. Exp Ther Med 2017;13:551-9. [PMID: 28352330 DOI: 10.3892/etm.2016.3968] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
12 Francis T, Graf A, Hodges K, Kennedy L, Hargrove L, Price M, Kearney K, Francis H. Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surg Nutr 2013;2:216-26. [PMID: 24570946 DOI: 10.3978/j.issn.2304-3881.2013.08.06] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Imamura T, Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2016; 22(25): 5627-5641 [PMID: 27433079 DOI: 10.3748/wjg.v22.i25.5627] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
14 Li S, Zhang X, Yan Y, Wang K, Rui D, Pang L, Li F. High Cancer Burden in Elderly Chinese, 2005-2011. Int J Environ Res Public Health. 2015;12:12196-12211. [PMID: 26426031 DOI: 10.3390/ijerph121012196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
15 Wright MJ, Overton HN, Teinor JA, Ding D, Burkhart RA, Cameron JL, He J, Wolfgang CL, Weiss MJ, Javed AA. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2020;24:1590-6. [DOI: 10.1007/s11605-019-04311-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Lian Y, Xiao C, Yan C, Chen D, Huang Q, Fan Y, Li Z, Xu H. Knockdown of pseudogene derived from lncRNA DUXAP10 inhibits cell proliferation, migration, invasion, and promotes apoptosis in pancreatic cancer. J Cell Biochem 2018;119:3671-82. [PMID: 29286182 DOI: 10.1002/jcb.26578] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
17 Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev Anticancer Ther. 2018;18:295-304. [PMID: 29334794 DOI: 10.1080/14737140.2018.1428093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
18 Mohammed H, Varoni EM, Cochis A, Cordaro M, Gallenzi P, Patini R, Staderini E, Lajolo C, Rimondini L, Rocchetti V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018;6:E115. [PMID: 30544974 DOI: 10.3390/biomedicines6040115] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
19 Agrawal S, Khanal B, Das U, Sah SP, Gupta RK. Pancreaticoduodenectomy: Impact of Volume on Outcomes at a Tertiary Care Center-Our Experience in Single Institute of Nepal. J Gastrointest Cancer 2021. [PMID: 34480743 DOI: 10.1007/s12029-021-00705-y] [Reference Citation Analysis]
20 Ding B, Wahid MA, Wang Z, Xie C, Thakkar A, Prabhu S, Wang J. Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells. Nanoscale 2017;9:11739-53. [PMID: 28782773 DOI: 10.1039/c7nr03016a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 9.7] [Reference Citation Analysis]
21 Kutkowska J, Strzadala L, Rapak A. Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci 2018;19:E3234. [PMID: 30347681 DOI: 10.3390/ijms19103234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Sun X, Zhang Y, Li B, Yang H. MTA1 promotes the invasion and migration of pancreatic cancer cells potentially through the HIF-α/VEGF pathway. Journal of Receptors and Signal Transduction 2018;38:352-8. [DOI: 10.1080/10799893.2018.1531887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
23 Bi Y, Shen W, Min M, Liu Y. MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma. Int J Mol Med 2017;39:900-6. [PMID: 28259961 DOI: 10.3892/ijmm.2017.2894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
24 Feng Y, Liu H, Duan B, Liu Z, Abbruzzese J, Walsh KM, Zhang X, Wei Q. Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. Carcinogenesis 2019;40:521-8. [PMID: 30794721 DOI: 10.1093/carcin/bgz029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
25 Zhou Q, Fengwei-Gao, Gong J, Xie Q, Liu Y, Wang Q, Lei Z. Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review. BMC Surg 2019;19:12. [PMID: 30691444 DOI: 10.1186/s12893-019-0476-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
26 Gao S, Pan Y, Song L, Dong L, Weng LI, Wang P, Hua Y, Chen Z, Liu L. Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells. Evid Based Complement Alternat Med 2016;2016:7028289. [PMID: 27829864 DOI: 10.1155/2016/7028289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Wang H, Wang X, Xu L, Lin Y, Zhang J, Cao H. Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer. Aging (Albany NY) 2020;12:18676-92. [PMID: 32950968 DOI: 10.18632/aging.103958] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Wild AT, Dholakia AS, Fan KY, Kumar R, Moningi S, Rosati LM, Laheru DA, Zheng L, De Jesus-Acosta A, Ellsworth SG, Hacker-Prietz A, Voong KR, Tran PT, Hruban RH, Pawlik TM, Wolfgang CL, Herman JM. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Gastrointest Oncol. 2015;6:115-125. [PMID: 25830031 DOI: 10.3978/j.issn.2078-6891.2014.091] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
29 Yu LM, Zhu YS, Xu CZ, Zhou LL, Xue ZX, Cai ZZ. High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients. Clin Transl Oncol 2019;21:924-32. [PMID: 30565085 DOI: 10.1007/s12094-018-02006-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
30 Peng J, Liu L, Huang D, Chen H, Dai M, Guo J, Zhang T, Liao Q, Jiang J, Wang W, Guo D, Cao D, Xuan Z, Li D, Zhao Y, Wu W. Impact of ischemia on sample quality of human pancreatic tissues. Pancreatology 2020;20:265-77. [PMID: 31956070 DOI: 10.1016/j.pan.2019.11.005] [Reference Citation Analysis]
31 Ye H, Zhou Q, Zheng S, Li G, Lin Q, Ye L, Wang Y, Wei L, Zhao X, Li W, Fu Z, Liu Y, Li Z, Chen R. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Cell Death Dis 2018;9:34. [PMID: 29348628 DOI: 10.1038/s41419-017-0052-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
32 Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A. Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program. Hered Cancer Clin Pract 2019;17:30. [PMID: 31666883 DOI: 10.1186/s13053-019-0129-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Shi X, Wang B, Feng X, Xu Y, Lu K, Sun M. circRNAs and Exosomes: A Mysterious Frontier for Human Cancer. Mol Ther Nucleic Acids. 2020;19:384-392. [PMID: 31887549 DOI: 10.1016/j.omtn.2019.11.023] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
34 Zhou M, Zhang Y, Wei H, He J, Wang D, Chen B, Zeng J, Gong A, Xu M. Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway. Oncol Lett 2018;15:3192-6. [PMID: 29435056 DOI: 10.3892/ol.2017.7672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Zhu Y, Tian J, Peng X, Wang X, Yang N, Ying P, Wang H, Li B, Li Y, Zhang M, Cai Y, Lu Z, Niu S, Li Y, Zhong R, Chang J, Miao X. A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. Eur J Cancer 2021;151:94-105. [PMID: 33975060 DOI: 10.1016/j.ejca.2021.04.008] [Reference Citation Analysis]
36 Jahny E, Yang H, Liu B, Jahnke B, Lademann F, Knösel T, Rümmele P, Grützmann R, Aust DE, Pilarsky C, Denz A. The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. PLoS One 2017;12:e0170390. [PMID: 28114355 DOI: 10.1371/journal.pone.0170390] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
37 Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018;8:1096-1111. [PMID: 29903880 DOI: 10.1158/2159-8290.cd-18-0275] [Cited by in Crossref: 113] [Cited by in F6Publishing: 72] [Article Influence: 37.7] [Reference Citation Analysis]
38 Yu Y, Tian L, Feng X, Cheng J, Gong Y, Liu X, Zhang Z, Yang X, He S, Li C, Huang Q. eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation. Cancer Letters 2016;375:31-8. [DOI: 10.1016/j.canlet.2016.02.052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
39 Wang-Gillam A, Williams K. Paving the road to clinical trial participation: removing road blocks and directing patients toward novel therapies. J Natl Compr Canc Netw 2015;13:118-20. [PMID: 25583774 DOI: 10.6004/jnccn.2015.0013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Gharibi A, Adamian Y, Kelber JA. Cellular and molecular aspects of pancreatic cancer. Acta Histochem 2016;118:305-16. [PMID: 26868366 DOI: 10.1016/j.acthis.2016.01.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
41 Hu Q, Wu W, Wang M, Shao S, Jin P, Chen Q, Bai H, Zhao X, Huang J, Wang J, Tang G, Liang T. Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule. Journal of Controlled Release 2020;317:67-77. [DOI: 10.1016/j.jconrel.2019.11.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Zhou X, Huang Z, Xu L, Zhu M, Zhang L, Zhang H, Wang X, Li H, Zhu W, Shu Y, Liu P. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget 2016;7:69616-24. [PMID: 27626307 DOI: 10.18632/oncotarget.11903] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
43 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 25.4] [Reference Citation Analysis]
44 Muth ST, Saung MT, Blair AB, Henderson MG, Thomas DL 2nd, Zheng L. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Cancer Lett 2021;499:99-108. [PMID: 33271264 DOI: 10.1016/j.canlet.2020.11.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Liang C, Shi S, Meng Q, Liang D, Hua J, Qin Y, Zhang B, Xu J, Ni Q, Yu X. MiR‐29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. Int J Cancer 2018;143:2919-31. [DOI: 10.1002/ijc.31654] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
46 Sun W, Ren Y, Lu Z, Zhao X. The potential roles of exosomes in pancreatic cancer initiation and metastasis. Mol Cancer 2020;19:135. [PMID: 32878635 DOI: 10.1186/s12943-020-01255-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
47 Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, van Oosten AF, Molenaar IQ, Cameron JL, Weiss MJ, Yang SC, Wolfgang CL, He J. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford) 2019;21:998-1008. [PMID: 30777697 DOI: 10.1016/j.hpb.2018.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
48 Sun Y, Peng W, He W, Luo M, Chang G, Shen J, Zhao X, Hu Y. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer. J Exp Clin Cancer Res 2018;37:166. [PMID: 30041673 DOI: 10.1186/s13046-018-0818-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
49 Huang S, Zhao J, Song J, Li Y, Zuo R, Sa Y, Ma Z, OuYang H. Interferon alpha-inducible protein 27 (IFI27) is a prognostic marker for pancreatic cancer based on comprehensive bioinformatics analysis. Bioengineered 2021;12:8515-28. [PMID: 34592906 DOI: 10.1080/21655979.2021.1985858] [Reference Citation Analysis]
50 Peters NA, Javed AA, Cameron JL, Makary MA, Hirose K, Pawlik TM, He J, Wolfgang CL, Weiss MJ. Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach? Ann Surg Oncol 2016;23:3757-64. [PMID: 27328946 DOI: 10.1245/s10434-016-5303-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
51 Mejia I, Bodapati S, Chen KT, Díaz B. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines 2020;8:E401. [PMID: 33050151 DOI: 10.3390/biomedicines8100401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Blair AB, Yin LD, Pu N, Yu J, Groot VP, Rozich NS, Javed AA, Zheng L, Cameron JL, Burkhart RA, Weiss MJ, Wolfgang CL, He J. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg 2021;274:162-9. [PMID: 32304375 DOI: 10.1097/SLA.0000000000003570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
53 He Z, Wu H, Jiao Y, Zheng J. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. Oncol Lett 2015;9:793-7. [PMID: 25624904 DOI: 10.3892/ol.2014.2751] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
54 Shen M, Wu MY, Chen LP, Zhi Q, Gong FR, Chen K, Li DM, Wu Y, Tao M, Li W. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Sci Rep 2015;5:11836. [PMID: 26135631 DOI: 10.1038/srep11836] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
55 Xu P, Wang X, Qian J, Li Z, Yao J, Xu A. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2021;100:e24651. [PMID: 33578593 DOI: 10.1097/MD.0000000000024651] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Zhang Z, Chen H, Lu Y, Feng T, Sun W. LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451. Int J Oncol 2018;52:1224-34. [PMID: 29532883 DOI: 10.3892/ijo.2018.4289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 赵银瑞, 张连峰, 赵萍, 周琳. miR216a及其靶基因JAK2CSK在胰腺癌中的表达及临床意义. 世界华人消化杂志 2015; 23(34): 5458-5464 [DOI: 10.11569/wcjd.v23.i34.5458] [Reference Citation Analysis]
58 Zhang Y, Kirane A, Huang H, Sorrelle NB, Burrows FJ, Dellinger MT, Brekken RA. Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. Mol Cancer Res 2019;17:348-55. [PMID: 30333153 DOI: 10.1158/1541-7786.MCR-18-0427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
59 Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H, Gao J, Zhang B, Xu W, Liu J. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015;25:561-573. [PMID: 25753158 DOI: 10.1038/cr.2015.30] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
60 Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D. Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncol Lett 2017;13:4027-34. [PMID: 28588695 DOI: 10.3892/ol.2017.5956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
62 Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R, Ehrmann J, Melichar B, Yogeswara T, Klos D, Vrba R, Havlik R, Mohelnikova-Duchonova B. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature. World J Gastroenterol 2017; 23(35): 6420-6428 [PMID: 29085191 DOI: 10.3748/wjg.v23.i35.6420] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
63 Luo AJ, Feng RH, Wang XW, Wang FZ. Older age at first birth is a risk factor for pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int 2016;15:125-30. [PMID: 27020627 DOI: 10.1016/s1499-3872(16)60063-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 617] [Article Influence: 131.4] [Reference Citation Analysis]
65 Dai H, Chen H, Liu W, You Y, Tan J, Yang A, Lai X, Bie P. Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study. J Cancer Res Clin Oncol 2016;142:2107-17. [PMID: 27444299 DOI: 10.1007/s00432-016-2206-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
66 Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer 2019;125:57-67. [PMID: 30457666 DOI: 10.1002/cncr.31787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
67 Kaur A, Riaz MS, Murugaiah V, Varghese PM, Singh SK, Kishore U. A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in Pancreatic Cancer Cell Lines via Fas-Mediated Pathway. Front Immunol 2018;9:1126. [PMID: 29915574 DOI: 10.3389/fimmu.2018.01126] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
68 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
69 Toriola AT, Ziegler M, Li Y, Pollak M, Stolzenberg-Solomon R. Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Ann Surg Oncol 2017;24:3212-9. [PMID: 28681154 DOI: 10.1245/s10434-017-5988-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
70 Zheng L. PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst. 2017;109. [PMID: 28131993 DOI: 10.1093/jnci/djw304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
71 Li X, Liang M, Jiang J, He R, Wang M, Guo X, Shen M, Qin R. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Int J Biol Sci 2018;14:1291-305. [PMID: 30123077 DOI: 10.7150/ijbs.26776] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
72 Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G. Reflex Testing for Germline BRCA1 , BRCA2 , PALB2 , and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
73 Fu H, Ni X, Ni F, Li D, Sun H, Kong H, Shan Y, Dai S. Study of the Mechanism by Which Curcumin Cooperates with Sestrin2 to Inhibit the Growth of Pancreatic Cancer. Gastroenterol Res Pract 2021;2021:7362233. [PMID: 34306067 DOI: 10.1155/2021/7362233] [Reference Citation Analysis]
74 Zhang Y, Li JH, Yuan QG, Cao G, Yang WB. Upregulation of LASP2 inhibits pancreatic cancer cell migration and invasion through suppressing TGF-β-induced EMT. J Cell Biochem 2019;120:13651-7. [PMID: 30945341 DOI: 10.1002/jcb.28638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Li L, Shang F, Zhang W, Zhang C, Li J, Wang C, Wei L. Role of vitamin D receptor gene polymorphisms in pancreatic cancer: a case-control study in China. Tumour Biol 2015;36:4707-14. [PMID: 25616697 DOI: 10.1007/s13277-015-3119-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
76 Sharbeen G, Youkhana J, Mawson A, McCarroll J, Nunez A, Biankin A, Johns A, Goldstein D, Phillips P. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget 2017;8:9216-29. [PMID: 27999205 DOI: 10.18632/oncotarget.13985] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
77 Bauer C, Kühnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters 2016;381:259-68. [DOI: 10.1016/j.canlet.2016.02.057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
78 Vicentini C, Calore F, Nigita G, Fadda P, Simbolo M, Sperandio N, Luchini C, Lawlor RT, Croce CM, Corbo V, Fassan M, Scarpa A. Exosomal miRNA signatures of pancreatic lesions. BMC Gastroenterol 2020;20:137. [PMID: 32375666 DOI: 10.1186/s12876-020-01287-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
79 Zhao X, Liu Y, Li Z, Zheng S, Wang Z, Li W, Bi Z, Li L, Jiang Y, Luo Y, Lin Q, Fu Z, Rufu C. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2018;22:655-667. [PMID: 28984028 DOI: 10.1111/jcmm.13351] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 17.3] [Reference Citation Analysis]
80 Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg 2019;270:340-7. [PMID: 29596120 DOI: 10.1097/SLA.0000000000002753] [Cited by in Crossref: 92] [Cited by in F6Publishing: 46] [Article Influence: 92.0] [Reference Citation Analysis]
81 Liang X, Cai W, Liu X, Jin M, Ruan L, Yan S. A radiomics model that predicts lymph node status in pancreatic cancer to guide clinical decision making: A retrospective study. J Cancer 2021;12:6050-7. [PMID: 34539878 DOI: 10.7150/jca.61101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Joliat GR, Allemann P, Labgaa I, Sulzer J, Vrochides D, Zerbi A, Nappo G, Perinel J, Adham M, Nentwich MF, Izbicki JR, Demartines N, Schäfer M. Prognostic value of positive histological margins in patients with pancreatic head ductal adenocarcinoma and lymph node involvement: an international multicentric study. HPB (Oxford) 2021;23:379-86. [PMID: 32782224 DOI: 10.1016/j.hpb.2020.07.008] [Reference Citation Analysis]
83 Zhang M, Yang J, Zhou J, Gao W, Zhang Y, Lin Y, Wang H, Ruan Z, Ni B. Prognostic Values of CD38 + CD101 + PD1 + CD8 + T Cells in Pancreatic Cancer. Immunological Investigations 2019;48:466-79. [DOI: 10.1080/08820139.2019.1566356] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
84 Lou UK, Wong CH, Chen Y. A simple and rapid colorimetric detection of serum lncRNA biomarkers for diagnosis of pancreatic cancer. RSC Adv 2020;10:8087-92. [DOI: 10.1039/c9ra07858d] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
85 Sun H, Xin R, Zheng C, Huang G. Aberrantly DNA Methylated-Differentially Expressed Genes in Pancreatic Cancer Through an Integrated Bioinformatics Approach. Front Genet 2021;12:583568. [PMID: 33833773 DOI: 10.3389/fgene.2021.583568] [Reference Citation Analysis]
86 Colloca GA, Venturino A, Guarneri D. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy. Med Oncol 2018;35. [DOI: 10.1007/s12032-018-1219-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang C, Yan H, Liu T. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Oncotarget 2015;6:37557-69. [PMID: 26485754 DOI: 10.18632/oncotarget.5317] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
88 Wang D, Wang R, Huang A, Fang Z, Wang K, He M, Xia JT, Li W. Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma. Oncol Rep 2018;40:2628-36. [PMID: 30226561 DOI: 10.3892/or.2018.6703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
89 Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol 2017;116:25-34. [PMID: 28591939 DOI: 10.1002/jso.24623] [Cited by in Crossref: 41] [Cited by in F6Publishing: 53] [Article Influence: 10.3] [Reference Citation Analysis]
90 Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019;269:1154-1162. [PMID: 31082915 DOI: 10.1097/sla.0000000000002734] [Cited by in Crossref: 83] [Cited by in F6Publishing: 50] [Article Influence: 83.0] [Reference Citation Analysis]
91 Huang X, Fan C, Zhu H, Le W, Cui S, Chen X, Li W, Zhang F, Huang Y, Sh D, Cui Z, Shao C, Chen B. Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer. Int J Nanomedicine 2018;13:2585-99. [PMID: 29750031 DOI: 10.2147/IJN.S158559] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
92 Li W, Chen C, Zhao X, Ye H, Zhao Y, Fu Z, Pan W, Zheng S, Wei L, Nong T, Li Z, Chen R. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. J Cell Mol Med 2017;21:2896-908. [PMID: 28544376 DOI: 10.1111/jcmm.13202] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
93 Zhou DD, Liu XF, Lu CW, Pant OP, Liu XD. Long non-coding RNA PVT1: Emerging biomarker in digestive system cancer. Cell Prolif. 2017;50. [PMID: 29027279 DOI: 10.1111/cpr.12398] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
94 Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2018;226:630-637.e1. [PMID: 29309945 DOI: 10.1016/j.jamcollsurg.2017.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
95 Murphy KJ, Chambers CR, Herrmann D, Timpson P, Pereira BA. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers (Basel) 2021;13:3481. [PMID: 34298706 DOI: 10.3390/cancers13143481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Duong HQ, You KS, Oh S, Kwak SJ, Seong YS. Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. Antioxidants (Basel) 2017;6:E52. [PMID: 28671577 DOI: 10.3390/antiox6030052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
97 Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel) 2016;8:E45. [PMID: 27096871 DOI: 10.3390/cancers8040045] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 20.0] [Reference Citation Analysis]
98 Sun H, Dai X, Han B. TRIM29 as a novel biomarker in pancreatic adenocarcinoma. Dis Markers 2014;2014:317817. [PMID: 24864129 DOI: 10.1155/2014/317817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
99 Gong J, Lu X, Xu J, Xiong W, Zhang H, Yu X. Coexpression of UCA1 and ITGA2 in pancreatic cancer cells target the expression of miR-107 through focal adhesion pathway. J Cell Physiol 2019;234:12884-96. [PMID: 30569514 DOI: 10.1002/jcp.27953] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
100 Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22(9): 2678-2700 [PMID: 26973408 DOI: 10.3748/wjg.v22.i9.2678] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 112] [Article Influence: 25.4] [Reference Citation Analysis]
101 Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol 2015; 21(41): 11793-11803 [PMID: 26557003 DOI: 10.3748/wjg.v21.i41.11793] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
102 Lahoud MJ, Kourie HR, Antoun J, El Osta L, Ghosn M. Road map for pain management in pancreatic cancer: A review. World J Gastrointest Oncol 2016; 8(8): 599-606 [PMID: 27574552 DOI: 10.4251/wjgo.v8.i8.599] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
103 Li X, Chen H, Liu Z, Ye Z, Gou S, Wang C. Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathway. Cancer Lett 2018;431:96-104. [PMID: 29859299 DOI: 10.1016/j.canlet.2018.05.043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
104 Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget 2014;5:7599-609. [PMID: 25277192 DOI: 10.18632/oncotarget.2281] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
105 Zhou Q, Xia Y, Lei Z. The predictive value of procalcitonin for postoperative early pancreatic fistula. BMC Surg 2020;20:90. [PMID: 32375732 DOI: 10.1186/s12893-020-00755-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
106 Xiong F, Wu GH, Wang B, Chen YJ. Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma. Cancer Cell Int 2021;21:411. [PMID: 34348730 DOI: 10.1186/s12935-021-02117-1] [Reference Citation Analysis]
107 Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Oncotarget 2017;8:31554-67. [PMID: 28404939 DOI: 10.18632/oncotarget.15767] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
108 Liu X, Zhang ZH, Jiang F. Hepatitis B virus infection increases the risk of pancreatic cancer: a meta-analysis. Scand J Gastroenterol 2021;56:252-8. [PMID: 33399501 DOI: 10.1080/00365521.2020.1868568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Xiao Q, Zhou D, Rucki AA, Williams J, Zhou J, Mo G, Murphy A, Fujiwara K, Kleponis J, Salman B, Wolfgang CL, Anders RA, Zheng S, Jaffee EM, Zheng L. Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Cancer Res 2016;76:5395-404. [PMID: 27496707 DOI: 10.1158/0008-5472.CAN-15-3264] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 10.4] [Reference Citation Analysis]
110 Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, Kupcinskas J, Malecka-Panas E, Neoptolemos JP, Niesen W, Vodicka P, Delle Fave G, Bueno-de-Mesquita HB, Gazouli M, Pacetti P, Di Leo M, Ito H, Klüter H, Soucek P, Corbo V, Yamao K, Hosono S, Kaaks R, Vashist Y, Gioffreda D, Strobel O, Shimizu Y, Dijk F, Andriulli A, Ivanauskas A, Bugert P, Tavano F, Vodickova L, Zambon CF, Lovecek M, Landi S, Key TJ, Boggi U, Pezzilli R, Jamroziak K, Mohelnikova-Duchonova B, Mambrini A, Bambi F, Busch O, Pazienza V, Valente R, Theodoropoulos GE, Hackert T, Capurso G, Cavestro GM, Pasquali C, Basso D, Sperti C, Matsuo K, Büchler M, Khaw KT, Izbicki J, Costello E, Katzke V, Michalski C, Stepien A, Rizzato C, Canzian F. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget 2016;7:57011-20. [PMID: 27486979 DOI: 10.18632/oncotarget.10935] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
111 Cai H, An Y, Chen X, Sun D, Chen T, Peng Y, Zhu F, Jiang Y, He X. Epigenetic inhibition of miR-663b by long non-coding RNA HOTAIR promotes pancreatic cancer cell proliferation via up-regulation of insulin-like growth factor 2. Oncotarget 2016;7:86857-70. [PMID: 27895308 DOI: 10.18632/oncotarget.13490] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 12.7] [Reference Citation Analysis]
112 Huang Y, Zheng J, Tan T, Song L, Huang S, Zhang Y, Lin L, Liu J, Zheng P, Chen X, Chen X, Ouyang X. BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis. Int J Biol Markers 2018;33:189-94. [PMID: 29076521 DOI: 10.5301/ijbm.5000310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
113 Li H, Liu X, Jiang S, Zhou X, Yao L, Di Y, Jiang Y, Gu J, Mao Y, Li J, Jin C, Yang P, Fu D. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Br J Cancer 2020;123:1012-23. [PMID: 32601462 DOI: 10.1038/s41416-020-0929-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Teng Y, Saito E, Abe SK, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Tsugane S. Female reproductive factors, exogenous hormone use, and pancreatic cancer risk: the Japan Public Health Center-based prospective study. European Journal of Cancer Prevention 2017;26:378-84. [DOI: 10.1097/cej.0000000000000358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Cancer Genome Atlas Research Network. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185-203.e13. [PMID: 28810144 DOI: 10.1016/j.ccell.2017.07.007] [Cited by in Crossref: 700] [Cited by in F6Publishing: 595] [Article Influence: 175.0] [Reference Citation Analysis]
116 Liou P, Kato T. Ex Vivo Resection and Autotransplantation for Pancreatic Neoplasms. Surgical Clinics of North America 2018;98:189-200. [DOI: 10.1016/j.suc.2017.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
117 Wang G, Pan J, Zhang L, Wang C. Overexpression of grainyhead-like transcription factor 2 is associated with poor prognosis in human pancreatic carcinoma. Oncol Lett 2019;17:1491-6. [PMID: 30675204 DOI: 10.3892/ol.2018.9741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
118 Varadhachary GR, Wolff RA. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? J Oncol Pract 2016;12:797-805. [PMID: 27621332 DOI: 10.1200/JOP.2016.015586] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
119 Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 2016;126:4140-56. [PMID: 27701147 DOI: 10.1172/JCI87734] [Cited by in Crossref: 107] [Cited by in F6Publishing: 75] [Article Influence: 21.4] [Reference Citation Analysis]
120 Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. Br J Cancer 2015;112:514-22. [PMID: 25584484 DOI: 10.1038/bjc.2014.659] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
121 Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, Su Z, Pai J, Oteiza KE, Griffith ME, Wahl RL, Tryggestad E, Pawlik T, Laheru DA, Wolfgang CL, Koong AC, Herman JM. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014;89:539-46. [PMID: 24751410 DOI: 10.1016/j.ijrobp.2014.02.031] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
122 Iwai T, Yoshimura M, Ashida R, Goto Y, Kishi T, Itasaka S, Shibuya K, Kanai M, Masui T, Fukuda A, Isoda H, Hiraoka M, Mizowaki T. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiat Oncol 2020;15:264. [PMID: 33187523 DOI: 10.1186/s13014-020-01712-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Shen ZT, Zhou H, Li AM, Ji XQ, Jiang CC, Yuan X, Li B, Zhu XX, Huang GC. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. J Cancer Res Clin Oncol 2020;146:417-28. [PMID: 31667573 DOI: 10.1007/s00432-019-03066-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
124 McCarroll JA, Sharbeen G, Liu J, Youkhana J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan M, Johns AL, Biankin AV, Kavallaris M, Phillips PA. βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget 2015;6:2235-49. [PMID: 25544769 DOI: 10.18632/oncotarget.2946] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
125 Ren C, Chen Y, Han C, Fu D, Chen H. Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer. Tumour Biol. 2014;35:11467-11472. [PMID: 25123265 DOI: 10.1007/s13277-014-2459-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
126 Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, Witkiewicz AK. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep 2014;9:2233-49. [PMID: 25497091 DOI: 10.1016/j.celrep.2014.11.025] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 15.6] [Reference Citation Analysis]
127 Cao L, Wu J, Qu X, Sheng J, Cui M, Liu S, Huang X, Xiang Y, Li B, Zhang X, Cui R. Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications. J Exp Clin Cancer Res 2020;39:267. [PMID: 33256814 DOI: 10.1186/s13046-020-01765-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
128 Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, Vatnitsky S, Chu WT. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol 2015;16:e93-e100. [PMID: 25638685 DOI: 10.1016/S1470-2045(14)70412-7] [Cited by in Crossref: 279] [Cited by in F6Publishing: 136] [Article Influence: 46.5] [Reference Citation Analysis]
129 Parekh A, Rosati LM, Chang DT, Goodman KA, Pawlik T, Koong AC, Herman JM. Stereotactic body radiation for pancreatic cancer: results of an international survey of practice patterns. J Radiat Oncol 2017;6:273-8. [DOI: 10.1007/s13566-016-0267-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
130 Ding G, Shen T, Yan C, Zhang M, Wu Z, Cao L. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. BMC Cancer 2019;19:1053. [PMID: 31694582 DOI: 10.1186/s12885-019-6145-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
131 Hu M, Chen X, Ma L, Ma Y, Li Y, Song H, Xu J, Zhou L, Li X, Jiang Y, Kong B, Huang P. AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis. J Cancer 2019;10:1870-8. [PMID: 31205544 DOI: 10.7150/jca.28299] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
132 Cong PF, Qu YC, Chen JP, Duan LL, Lin CJ, Zhu XL, Li-Ling J, Zhang MX. Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells. World J Gastroenterol 2015; 21(15): 4526-4535 [PMID: 25914461 DOI: 10.3748/wjg.v21.i15.4526] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
133 Hou J, Wang Z, Li H, Zhang H, Luo L. Gene Signature and Identification of Clinical Trait-Related m6 A Regulators in Pancreatic Cancer. Front Genet 2020;11:522. [PMID: 32754191 DOI: 10.3389/fgene.2020.00522] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
134 Luo H, Galvão DA, Newton RU, Lopez P, Tang C, Fairman CM, Spry N, Taaffe DR. Exercise Medicine in the Management of Pancreatic Cancer: A Systematic Review. Pancreas 2021;50:280-92. [PMID: 33835957 DOI: 10.1097/MPA.0000000000001753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
135 Zhu J, Chen Y, Ji Y, Yu Y, Jin Y, Zhang X, Zhou J. Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells: Gemcitabine Induces Apoptosis and Autophagy. Biotechnology and Applied Biochemistry 2018;65:665-71. [DOI: 10.1002/bab.1657] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
136 Xie X, Wu MY, Shou LM, Chen LP, Gong FR, Chen K, Li DM, Duan WM, Xie YF, Mao YX, Li W, Tao M. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett 2015;9:837-44. [PMID: 25624908 DOI: 10.3892/ol.2014.2711] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
137 Chen C, Xie Z, Shen Y, Xia SF. The Roles of Thyroid and Thyroid Hormone in Pancreas: Physiology and Pathology. Int J Endocrinol 2018;2018:2861034. [PMID: 30013597 DOI: 10.1155/2018/2861034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
138 Yan K, Zhang Y, Mu C, Xu Q, Jing X, Wang D, Dang D, Meng L, Ma J. Versatile Nanoplatforms with enhanced Photodynamic Therapy: Designs and Applications. Theranostics 2020;10:7287-318. [PMID: 32641993 DOI: 10.7150/thno.46288] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 20.0] [Reference Citation Analysis]
139 Lian Y, Wang J, Feng J, Ding J, Ma Z, Li J, Peng P, De W, Wang K. Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer. Tumour Biol 2016;37:14929-37. [PMID: 27644252 DOI: 10.1007/s13277-016-5380-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
140 Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, Fishman EK, Kamel I, Weiss MJ, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH. The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia? Cancer Res 2014;74:3381-9. [DOI: 10.1158/0008-5472.can-14-0734] [Cited by in Crossref: 144] [Cited by in F6Publishing: 80] [Article Influence: 20.6] [Reference Citation Analysis]
141 Manning AA, Zhao L, Zhu Z, Xiao H, Redington CG, Ding VA, Stewart-Hester T, Bai Q, Dunlap J, Wakefield MR, Fang Y. IL-39 acts as a friend to pancreatic cancer. Med Oncol 2018;36:12. [PMID: 30506430 DOI: 10.1007/s12032-018-1236-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
142 Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta 2016;1865:23-34. [PMID: 26145884 DOI: 10.1016/j.bbcan.2015.06.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 56] [Article Influence: 7.5] [Reference Citation Analysis]
143 Underwood PW, Zhang DY, Cameron ME, Gerber MH, Delitto D, Maduka MU, Cooper KJ, Han S, Hughes SJ, Judge SM, Judge AR, Trevino JG. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Cancers (Basel) 2020;12:E329. [PMID: 32024069 DOI: 10.3390/cancers12020329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
144 Macarulla T, Carrato A, Díaz R, García A, Laquente B, Sastre J, Álvarez R, Muñoz A, Hidalgo M. Management and supportive treatment of frail patients with metastatic pancreatic cancer. J Geriatr Oncol 2019;10:398-404. [PMID: 30005980 DOI: 10.1016/j.jgo.2018.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
145 Tong J, Ma X, Yu H, Yang J. SNHG15: a promising cancer-related long noncoding RNA. Cancer Manag Res 2019;11:5961-9. [PMID: 31308739 DOI: 10.2147/CMAR.S208054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
146 Yuan YH, Zhou J, Zhang Y, Xu MD, Wu J, Li W, Wu MY, Li DM. Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis. Oncol Lett 2019;18:1117-32. [PMID: 31423172 DOI: 10.3892/ol.2019.10444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
147 Zhang YB, Fei HX, Guo J, Zhang XJ, Wu SL, Zhong LL. Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway. Oncol Lett 2019;18:4403-14. [PMID: 31611949 DOI: 10.3892/ol.2019.10790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Du Y, Zhao B, Liu Z, Ren X, Zhao W, Li Z, You L, Zhao Y. Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. J Cancer 2017;8:513-22. [PMID: 28367231 DOI: 10.7150/jca.17622] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
149 Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy 2015;7:363-76. [PMID: 25917628 DOI: 10.2217/imt.15.9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
150 Huang L, Jansen L, Balavarca Y, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Primic-Žakelj M, Zadnik V, Besselink MG, Schrotz-King P, Brenner H. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med 2018;16:125. [PMID: 30126408 DOI: 10.1186/s12916-018-1120-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 14.0] [Reference Citation Analysis]
151 Wang J, Guo XJ, Ding YM, Jiang JX. miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. World J Gastroenterol 2017; 23(9): 1594-1601 [PMID: 28321160 DOI: 10.3748/wjg.v23.i9.1594] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
152 Wang C, Liu B, Xu X, Zhuang B, Li H, Yin J, Cong M, Xu W, Lu A. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine. Oncotarget 2016;7:8360-72. [PMID: 26840019 DOI: 10.18632/oncotarget.7073] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
153 Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014;31:346. [PMID: 25412939 DOI: 10.1007/s12032-014-0346-4] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 15.3] [Reference Citation Analysis]
154 Wang S, Lei Y, Cai Z, Ye X, Li L, Luo X, Yu C. Girdin regulates the proliferation and apoptosis of pancreatic cancer cells via the PI3K/Akt signalling pathway. Oncol Rep 2018;40:599-608. [PMID: 29901184 DOI: 10.3892/or.2018.6469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
155 Li Z, Jia Z, Gao Y, Xie D, Wei D, Cui J, Mishra L, Huang S, Zhang Y, Xie K. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Clin Cancer Res 2015;21:844-53. [PMID: 25501129 DOI: 10.1158/1078-0432.CCR-14-2437] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
156 Blair AB, Krell RW, Ejaz A, Groot VP, Gemenetzis G, Padussis JC, Falconi M, Wolfgang CL, Weiss MJ, Are C, He J, Reames BN. Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume. J Gastrointest Surg 2021. [PMID: 34027578 DOI: 10.1007/s11605-021-05034-w] [Reference Citation Analysis]
157 Du X, He K, Huang Y, Xu Z, Kong M, Zhang J, Cao J, Teng L. Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target. Int J Oncol 2020;56:761-71. [PMID: 32124956 DOI: 10.3892/ijo.2020.4965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Chen JQ, Tao YP, Hong YG, Li HF, Huang ZP, Xu XF, Zheng H, Hu LK. M6A-mediated up-regulation of LncRNA LIFR-AS1 enhances the progression of pancreatic cancer via miRNA-150-5p/ VEGFA/Akt signaling. Cell Cycle 2021;20:2507-18. [PMID: 34658294 DOI: 10.1080/15384101.2021.1991122] [Reference Citation Analysis]
159 Chen W, Huang C, Cheng W, Hung C, Huang M, Tai C, Liu Y, Chen C, Chang Y. Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil. Tumor Biol 2015;36:9537-44. [DOI: 10.1007/s13277-015-3668-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
160 Upadhrasta S, Zheng L. Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in the Tumor Microenvironment. J Clin Med. 2019;8. [PMID: 31527414 DOI: 10.3390/jcm8091472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
161 Wang W, Li X, Guan C, Hu Z, Zhao Y, Li W, Jiang X. LncRNA PCAT6 promotes the proliferation, migration and invasion of pancreatic ductal adenocarcinoma via regulating miR-185-5p/CBX2 axis. Pathol Res Pract 2020;216:153074. [PMID: 32825947 DOI: 10.1016/j.prp.2020.153074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
162 Li HZ, Peng CY, Shen SS, Wang L, Zhang S, Xu GF, Kong B, Friess H, Zou XP, Lv Y. Factors affecting the accuracy of endoscopic ultrasound‐guided fine needle aspiration for the diagnosis of small (≤20 mm) pancreatic lesions. J Dig Dis 2020;21:416-21. [DOI: 10.1111/1751-2980.12875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A, Ibarrola-Villava M. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel) 2021;13:994. [PMID: 33673558 DOI: 10.3390/cancers13050994] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Li X, Liu Z, Ye Z, Gou S, Wang C. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data. Pancreatology 2018;18:133-8. [PMID: 29170052 DOI: 10.1016/j.pan.2017.11.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
165 Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther. 2015;15:505-516. [PMID: 25582170 DOI: 10.1517/14712598.2015.1001734] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
166 Frey N, Venturelli S, Zender L, Bitzer M. Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. Nat Rev Gastroenterol Hepatol. 2018;15:81-95. [PMID: 29184185 DOI: 10.1038/nrgastro.2017.146] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
167 Wang Z, Shen W, Li X, Feng Y, Qian K, Wang G, Gao Y, Xu X, Zhang S, Yue L, Cao J. The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells. Drug Des Devel Ther 2020;14:3099-110. [PMID: 32801648 DOI: 10.2147/DDDT.S242557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
168 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Schunke KJ, Rosati LM, Zahurak M, Herman JM, Narang AK, Usach I, Klein AP, Yeo CJ, Korman LT, Hruban RH, Cameron JL, Laheru DA, Abrams RA. Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Adv Radiat Oncol 2018;3:42-51. [PMID: 29556579 DOI: 10.1016/j.adro.2017.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
170 Wang Y, Li Z, Zheng S, Zhou Y, Zhao L, Ye H, Zhao X, Gao W, Fu Z, Zhou Q, Liu Y, Chen R. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget 2015;6:35684-98. [PMID: 26447755 DOI: 10.18632/oncotarget.5533] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 11.4] [Reference Citation Analysis]
171 Cheng Z, Rosati LM, Chen L, Mian OY, Cao Y, Villafania M, Nakatsugawa M, Moore JA, Robertson SP, Jackson J, Hacker-Prietz A, He J, Wolfgang CL, Weiss MJ, Herman JM, Narang AK, McNutt TR. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Adv Radiat Oncol 2018;3:601-10. [PMID: 30370361 DOI: 10.1016/j.adro.2018.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
172 Xie S, Qin J, Liu S, Zhang Y, Wang J, Shi X, Li D, Zhou J, Liu M. Cep70 overexpression stimulates pancreatic cancer by inducing centrosome abnormality and microtubule disorganization. Sci Rep 2016;6:21263. [PMID: 26893288 DOI: 10.1038/srep21263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
173 Li L, Zhang X, Liu N, Chen X, Peng C. LINC00473: A novel oncogenic long noncoding RNA in human cancers. J Cell Physiol 2021;236:4174-83. [PMID: 33222224 DOI: 10.1002/jcp.30176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
174 Li Z, Yanfang W, Li J, Jiang P, Peng T, Chen K, Zhao X, Zhang Y, Zhen P, Zhu J, Li X. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 2018;432:237-250. [PMID: 29709702 DOI: 10.1016/j.canlet.2018.04.035] [Cited by in Crossref: 127] [Cited by in F6Publishing: 146] [Article Influence: 42.3] [Reference Citation Analysis]
175 Yoshida S, Ito Z, Suka M, Bito T, Kan S, Akasu T, Saruta M, Okamoto M, Kitamura H, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Sugiyama H, Koido S. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. Cancer Invest 2019;37:463-77. [PMID: 31490702 DOI: 10.1080/07357907.2019.1661427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
176 Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker-Prietz A, Chen L, Laheru DA, De Jesus-Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang CY, Zheng L. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Med 2017;6:1552-62. [PMID: 28639410 DOI: 10.1002/cam4.1104] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
177 Zhang C, Yang G, Ling Y, Chen G, Zhou T. The early diagnosis of pancreatic cancer and diabetes: what's the relationship? J Gastrointest Oncol. 2014;5:481-488. [PMID: 25436129 DOI: 10.3978/j.issn.2078-6891.2014.055] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
178 Moschovis D, Gazouli M, Tzouvala M, Vezakis A, Karamanolis G. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Ann Gastroenterol 2017;30:622-8. [PMID: 29118556 DOI: 10.20524/aog.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
179 Shi LE, Shang X, Nie KC, Xu Q, Chen NB, Zhu ZZ. Identification of potential crucial genes associated with the pathogenesis and prognosis of pancreatic adenocarcinoma. Oncol Lett 2020;20:60. [PMID: 32793313 DOI: 10.3892/ol.2020.11921] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Zheng S, Wang X, Weng YH, Jin X, Ji JL, Guo L, Hu B, Liu N, Cheng Q, Zhang J, Bai H, Yang T, Xia XH, Zhang HY, Gao S, Huang Y. siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. Mol Ther Nucleic Acids 2018;12:805-16. [PMID: 30153565 DOI: 10.1016/j.omtn.2018.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
181 Vera R, Ferrández A, Ferrer CJ, Flores C, Joaquín C, López S, Martín T, Martín E, Marzo M, Sarrión A, Vaquero E, Zapatero A, Aparicio J. Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies. Clin Transl Oncol 2017;19:834-43. [PMID: 28105537 DOI: 10.1007/s12094-016-1609-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
182 Jurcak N, Zheng L. Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve. Pharmacol Ther. 2019;pii:S0163-7258(19)30073-7. [PMID: 31047906 DOI: 10.1016/j.pharmthera.2019.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
183 Choe JW, Hyun JJ. [Relief of Cancer Pain in Patients with Pancreatic Cancer]. Korean J Gastroenterol 2019;74:81-6. [PMID: 31438659 DOI: 10.4166/kjg.2019.74.2.81] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
185 Hu W, Han Y, Yang W, Xu B, Zhang W, Jin Z, Chen F. Novel role of sex-determining region Y-box 7 (SOX7) in tumor biology and cardiovascular developmental biology. Semin Cancer Biol 2020;67:49-56. [PMID: 31473269 DOI: 10.1016/j.semcancer.2019.08.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Jiang SH, Li J, Dong FY, Yang JY, Liu DJ, Yang XM, Wang YH, Yang MW, Fu XL, Zhang XX, Li Q, Pang XF, Huo YM, Li J, Zhang JF, Lee HY, Lee SJ, Qin WX, Gu JR, Sun YW, Zhang ZG. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. Gastroenterology. 2017;153:277-291.e19. [PMID: 28315323 DOI: 10.1053/j.gastro.2017.03.008] [Cited by in Crossref: 94] [Cited by in F6Publishing: 100] [Article Influence: 23.5] [Reference Citation Analysis]
187 Huang J, Chen Z, Ding C, Lin S, Wan D, Ren K. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma. Front Oncol 2021;11:711402. [PMID: 34497764 DOI: 10.3389/fonc.2021.711402] [Reference Citation Analysis]
188 Lian Y, Yang J, Lian Y, Xiao C, Hu X, Xu H. DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2. Cancer Commun (Lond) 2018;38:64. [PMID: 30367681 DOI: 10.1186/s40880-018-0333-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
189 Feng Y, Jiang Y, Hao F. GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments. J Transl Med 2021;19:373. [PMID: 34461940 DOI: 10.1186/s12967-021-03050-7] [Reference Citation Analysis]
190 Habib JR, Wolfgang CL. Commentary: Anatomic versus biologic resectability: The role of predictive biomarkers in guiding surgical management. Surgery 2020;168:1017-8. [PMID: 32900493 DOI: 10.1016/j.surg.2020.07.032] [Reference Citation Analysis]
191 Liu Y, Shao L, Chen K, Wang Z, Wang J, Jing W, Hu M. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. Onco Targets Ther 2018;11:8371-9. [PMID: 30568460 DOI: 10.2147/OTT.S181792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
192 Wang ZQ, Zhang F, Deng T, Zhang L, Feng F, Wang FH, Wang W, Wang DS, Luo HY, Xu RH, Ba Y, Li YH. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond). 2019;39:26. [PMID: 31068222 DOI: 10.1186/s40880-019-0367-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
193 Fujiwara M, Kanayama K, Hirokawa YS, Shiraishi T. ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo. Oncol Lett 2016;11:2773-9. [PMID: 27073551 DOI: 10.3892/ol.2016.4289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
194 Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database. Radiat Oncol 2020;15:139. [PMID: 32493354 DOI: 10.1186/s13014-020-01569-5] [Reference Citation Analysis]
195 Xu J, Xu W, Yang X, Liu Z, Sun Q. LncRNA HCG11/miR-579-3p/MDM2 axis modulates malignant biological properties in pancreatic carcinoma via Notch/Hes1 signaling pathway. Aging (Albany NY) 2021;13:16471-84. [PMID: 34230221 DOI: 10.18632/aging.203167] [Reference Citation Analysis]
196 Li Q, Lei C, Lu C, Wang J, Gao M, Gao W. LINC01232 exerts oncogenic activities in pancreatic adenocarcinoma via regulation of TM9SF2. Cell Death Dis 2019;10:698. [PMID: 31541081 DOI: 10.1038/s41419-019-1896-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
197 Zhao Y, Zhou P, Ji W, Wang H, Fang M, Wang M, Yin Y, Jin G, Gao C. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer. Clin Exp Med 2017;17:9-18. [DOI: 10.1007/s10238-015-0401-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
198 Lemke J, Scheele J, Kapapa T, von Karstedt S, Wirtz CR, Henne-Bruns D, Kornmann M. Brain metastases in gastrointestinal cancers: is there a role for surgery? Int J Mol Sci 2014;15:16816-30. [PMID: 25247579 DOI: 10.3390/ijms150916816] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
199 Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J, Huang K. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol Res Pract 2016;2016:8962321. [PMID: 26941789 DOI: 10.1155/2016/8962321] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 12.2] [Reference Citation Analysis]
200 Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande SV, Banerjee S. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. Curr Genomics 2018;19:444-63. [PMID: 30258276 DOI: 10.2174/1389202919666180221160753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
201 Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. Onco Targets Ther 2020;13:12705-20. [PMID: 33335406 DOI: 10.2147/OTT.S220971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Means N, Elechalawar CK, Chen WR, Bhattacharya R, Mukherjee P. Revealing macropinocytosis using nanoparticles. Mol Aspects Med 2021;:100993. [PMID: 34281720 DOI: 10.1016/j.mam.2021.100993] [Reference Citation Analysis]
203 Guo C, Chen X, Wang Z, Xiao W, Wang Q, Sun K, Zhuge X. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. Oncotarget 2017;8:42962-73. [PMID: 28487490 DOI: 10.18632/oncotarget.17309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
204 Li BY, He LJ, Zhang XL, Liu H, Liu B. High expression of RAB38 promotes malignant progression of pancreatic cancer. Mol Med Rep 2019;19:909-18. [PMID: 30569114 DOI: 10.3892/mmr.2018.9732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
205 Yan TT, Fu XL, Li J, Bian YN, Liu DJ, Hua R, Ren LL, Li CT, Sun YW, Chen HY, Fang JY, Hong J. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Oncotarget 2015;6:37028-42. [PMID: 26498693 DOI: 10.18632/oncotarget.5939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
206 Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenery D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, Bouganim N, Kavan P, Arena G, Barkun J, Chaudhury P, Gallinger S, Foulkes WD, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr Oncol 2015;22:113-21. [PMID: 25908910 DOI: 10.3747/co.22.2300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
207 Durante M, Tommasino F, Yamada S. Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer. Front Oncol 2015;5:145. [PMID: 26217585 DOI: 10.3389/fonc.2015.00145] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
208 Gu JF, Fu W, Qian HX, Gu WX, Zong Y, Chen Q, Lu L. TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma. World J Gastroenterol 2020; 26(25): 3586-3602 [PMID: 32742128 DOI: 10.3748/wjg.v26.i25.3586] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
209 Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016;115:442-453. [PMID: 27441498 DOI: 10.1038/bjc.2016.215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
210 Chang J, Tian J, Zhu Y, Zhong R, Zhai K, Li J, Ke J, Han Q, Lou J, Chen W, Zhu B, Shen N, Zhang Y, Gong Y, Yang Y, Zou D, Peng X, Zhang Z, Zhang X, Huang K, Yang M, Wang L, Wu C, Lin D, Miao X. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Nat Commun 2018;9:3688. [PMID: 30206226 DOI: 10.1038/s41467-018-06136-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
211 Park JY, Cho YL, Chae JR, Moon SH, Cho WG, Choi YJ, Lee SJ, Kang WJ. Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer. Mol Ther Nucleic Acids 2018;12:543-53. [PMID: 30195790 DOI: 10.1016/j.omtn.2018.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
212 Cui L, Lv N, Li B, Tao J, Zheng X, Yan Y, Liu C. Serum CA 19-9 Level is Correlated to the Clinical Characteristics and Chronic Complications of Patients Newly Diagnosed with Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2021;129:581-6. [PMID: 31461764 DOI: 10.1055/a-0994-9970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Coveler AL, Mizrahi J, Eastman B, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S; Precision Promise Consortium. Pancreas Cancer-Associated Pain Management. Oncologist 2021;26:e971-82. [PMID: 33885205 DOI: 10.1002/onco.13796] [Reference Citation Analysis]
214 Cheng C, Sui B, Wang M, Hu X, Shi S, Xu P. Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy. Adv Healthc Mater 2020;9:e2001128. [PMID: 32893507 DOI: 10.1002/adhm.202001128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
215 Di Marco M, Rubbi I, Baldi A, Di Lorenzo R, Magnani D, Cremonini V, Sarli L, Artioli G, Ferri P. Evaluation of fatigue in patients with pancreatic cancer receiving chemotherapy treatment: a cross-sectional observational study. Acta Biomed 2018;89:18-27. [PMID: 29644986 DOI: 10.23750/abm.v89i4-S.7063] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
216 Javed AA, Bleich K, Bagante F, He J, Weiss MJ, Wolfgang CL, Fishman EK. Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings. Abdom Radiol (NY) 2018;43:1193-203. [PMID: 28828527 DOI: 10.1007/s00261-017-1290-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
217 Zolghadri Y, Pal Choudhuri S, Ocal O, Layeghi-Ghalehsoukhteh S, Berhe F, Hale MA, Wilkie TM. Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. Am J Pathol 2018;188:616-26. [PMID: 29248457 DOI: 10.1016/j.ajpath.2017.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
218 Sell NM, Lee GC, Fernández-Del Castillo C, Ferrone CR, Warshaw AL, Hong TS, Blaszkowsky LS, Lillemoe KD, Qadan M. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas 2020;49:897-903. [PMID: 32658070 DOI: 10.1097/MPA.0000000000001590] [Reference Citation Analysis]
219 Yuen A, Díaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2014;2:91-106. [PMID: 27774469 DOI: 10.2147/HP.S52636] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
220 Habtezion A, Edderkaoui M, Pandol SJ. Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett 2016;381:211-6. [PMID: 26708507 DOI: 10.1016/j.canlet.2015.11.049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
221 Hu S, Chen Z, Gu J, Tan L, Zhang M, Lin W. TLE2 is associated with favorable prognosis and regulates cell growth and gemcitabine sensitivity in pancreatic cancer. Ann Transl Med 2020;8:1017. [PMID: 32953817 DOI: 10.21037/atm-20-5492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Tao M, Liu L, Shen M, Zhi Q, Gong FR, Zhou BP, Wu Y, Liu H, Chen K, Shen B, Wu MY, Shou LM, Li W. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac. Cell Cycle 2016;15:381-93. [PMID: 26761431 DOI: 10.1080/15384101.2015.1127468] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
223 Modi S, Kir D, Giri B, Majumder K, Arora N, Dudeja V, Banerjee S, Saluja AK. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. J Gastrointest Surg 2016;20:13-23; discussion 23-4. [PMID: 26503259 DOI: 10.1007/s11605-015-3000-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
224 Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics 2019;20:113-27. [PMID: 30539680 DOI: 10.2217/pgs-2018-0073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 Chen J, Li H, Xu W, Guo X. Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer. BMC Gastroenterol 2021;21:58. [PMID: 33568105 DOI: 10.1186/s12876-021-01635-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Zhu X, Kong Q, Niu X, Chen L, Ge C. Mapping Intellectual Structure and Research Performance for the Nanoparticles in Pancreatic Cancer Field. Int J Nanomedicine 2020;15:5503-16. [PMID: 32801702 DOI: 10.2147/IJN.S253599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Xu X, Xiao Y, Hong B, Hao B, Qian Y. Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer. Cancer Biomark 2019;25:251-7. [PMID: 31282407 DOI: 10.3233/CBM-190067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
228 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
229 Xu D, Yang F, Wu K, Xu X, Zeng K, An Y, Xu F, Xun J, Lv X, Zhang X, Yang X, Xu L. Lost miR-141 and upregulated TM4SF1 expressions associate with poor prognosis of pancreatic cancer: regulation of EMT and angiogenesis by miR-141 and TM4SF1 via AKT. Cancer Biol Ther. 2020;21:354-363. [PMID: 31906774 DOI: 10.1080/15384047.2019.1702401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
230 Zacharie B, Abbott SD, Duceppe JS, Gagnon L, Grouix B, Geerts L, Gervais L, Sarra-Bournet F, Perron V, Wilb N, Penney CL, Laurin P. Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation. ChemistryOpen 2018;7:737-49. [PMID: 30258746 DOI: 10.1002/open.201800136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
231 Shi H, Wei Y, Cheng S, Lu Z, Zhang K, Jiang K, Xu Q. Survival prediction after upfront surgery in patients with pancreatic ductal adenocarcinoma: Radiomic, clinic-pathologic and body composition analysis. Pancreatology 2021;21:731-7. [PMID: 33678581 DOI: 10.1016/j.pan.2021.02.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
232 Wei L, Lin Q, Lu Y, Li G, Huang L, Fu Z, Chen R, Zhou Q. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation. Cell Death Dis 2021;12:334. [PMID: 33782384 DOI: 10.1038/s41419-021-03574-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
233 Fang Z, Meng Q, Zhang B, Shi S, Liu J, Liang C, Hua J, Yu X, Xu J, Wang W. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. Aging (Albany NY) 2020;13:2031-48. [PMID: 33318293 DOI: 10.18632/aging.202199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients. Diagn Pathol 2014;9:79. [PMID: 24708709 DOI: 10.1186/1746-1596-9-79] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
235 Crawley AS, O'Kennedy RJ. The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Expert Rev Mol Diagn 2015;15:1339-53. [PMID: 26394703 DOI: 10.1586/14737159.2015.1083862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
236 Tomás-Bort E, Kieler M, Sharma S, Candido JB, Loessner D. 3D approaches to model the tumor microenvironment of pancreatic cancer. Theranostics 2020;10:5074-89. [PMID: 32308769 DOI: 10.7150/thno.42441] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 23.0] [Reference Citation Analysis]
237 Lorkowski ME, Atukorale PU, Bielecki PA, Tong KH, Covarrubias G, Zhang Y, Loutrianakis G, Moon TJ, Santulli AR, Becicka WM, Karathanasis E. Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. J Control Release 2021;330:1095-105. [PMID: 33188827 DOI: 10.1016/j.jconrel.2020.11.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
238 Poruk KE, Kim Y, Cameron JL, He J, Eckhauser FE, Rezaee N, Herman J, Laheru D, Zheng L, Fishman EK, Hruban RH, Pawlik TM, Wolfgang CL, Weiss MJ. What is the Significance of Indeterminate Pulmonary Nodules in Patients Undergoing Resection for Pancreatic Adenocarcinoma? J Gastrointest Surg 2015;19:841-7. [PMID: 25595307 DOI: 10.1007/s11605-014-2740-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
239 Wang X, Hu LP, Qin WT, Yang Q, Chen DY, Li Q, Zhou KX, Huang PQ, Xu CJ, Li J, Yao LL, Wang YH, Tian GA, Yang JY, Yang MW, Liu DJ, Sun YW, Jiang SH, Zhang XL, Zhang ZG. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat Commun 2021;12:174. [PMID: 33420030 DOI: 10.1038/s41467-020-20447-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
240 Si L, Xu L, Yin L, Qi Y, Han X, Xu Y, Zhao Y, Liu K, Peng J. Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway. Br J Pharmacol 2017;174:553-68. [PMID: 28095588 DOI: 10.1111/bph.13718] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
241 Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J Gastrointest Surg 2019;23:112-21. [PMID: 30242644 DOI: 10.1007/s11605-018-3966-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
242 Jing S, Tian J, Zhang Y, Chen X, Zheng S. Identification of a new pseudogenes/lncRNAs-hsa-miR-26b-5p-COL12A1 competing endogenous RNA network associated with prognosis of pancreatic cancer using bioinformatics analysis. Aging (Albany NY) 2020;12:19107-28. [PMID: 33027767 DOI: 10.18632/aging.103709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
243 Castiglione R, Calogero AE, Vicari E, Calabrini G, Cosentino A, D'Agati P, Fraggetta F, Salemi M. Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma. Case Rep Gastrointest Med 2020;2020:2717150. [PMID: 32850156 DOI: 10.1155/2020/2717150] [Reference Citation Analysis]
244 Mosquera C, Maglic D, Zervos EE. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Cancer Genet 2016;209:567-81. [PMID: 27613577 DOI: 10.1016/j.cancergen.2016.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
245 Xiang J, Hu Q, Qin Y, Ji S, Xu W, Liu W, Shi S, Liang C, Liu J, Meng Q, Liang D, Ni Q, Xu J, Zhang B, Yu X. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Cell Death Dis 2018;9:321. [PMID: 29476053 DOI: 10.1038/s41419-018-0367-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
246 Gemenetzis G, Groot VP, Blair AB, Ding D, Thakker SS, Fishman EK, Cameron JL, Makary MA, Weiss MJ, Wolfgang CL, He J. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. J Surg Oncol 2018;118:1277-84. [PMID: 30380143 DOI: 10.1002/jso.25288] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
247 Wang J, Chen Y, Li X, Zou X. Perineural Invasion and Associated Pain Transmission in Pancreatic Cancer. Cancers (Basel) 2021;13:4594. [PMID: 34572820 DOI: 10.3390/cancers13184594] [Reference Citation Analysis]
248 Xie X, Tu J, You H, Hu B. Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer. Drug Des Devel Ther 2017;11:1439-51. [PMID: 28553074 DOI: 10.2147/DDDT.S133172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
249 Blair AB, Zheng L. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. Chin Clin Oncol 2017;6:31. [PMID: 28705008 DOI: 10.21037/cco.2017.06.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
250 Jin W, Xu HX, Zhang SR, Li H, Wang WQ, Gao HL, Wu CT, Xu JZ, Qi ZH, Li S, Ni QX, Liu L, Yu XJ. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019;26:635-643. [PMID: 30374923 DOI: 10.1245/s10434-018-6941-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
251 Yang B, Xie J, Li Z, Su D, Lin L, Guo X, Fu Z, Zhou Q, Lu Y. Seven-gene signature on tumor microenvironment for predicting the prognosis of patients with pancreatic cancer. Gland Surg 2021;10:1397-409. [PMID: 33968691 DOI: 10.21037/gs-21-28] [Reference Citation Analysis]
252 Werthmann PG, Inter P, Welsch T, Sturm AK, Grützmann R, Debus M, Sterner MG, Kienle GS. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report.Medicine (Baltimore). 2018;97:e13243. [PMID: 30544385 DOI: 10.1097/MD.0000000000013243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
253 Arnoletti JP, Zhu X, Almodovar AJ, Veldhuis PP, Sause R, Griffith E, Corpus G, Chang JC, Fanaian N, Litherland SA. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation. Pancreas 2017;46:116-23. [DOI: 10.1097/mpa.0000000000000667] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
254 Huang X, Ding L, Liu X, Tong R, Ding J, Qian Z, Cai L, Zhang P, Li D. Regulation of tumor microenvironment for pancreatic cancer therapy. Biomaterials 2021;270:120680. [PMID: 33588140 DOI: 10.1016/j.biomaterials.2021.120680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
255 Zhou C, Chu Z, Hou W, Wang X. Lanthanide-Doped Upconversion-Linked Immunosorbent Assay for the Sensitive Detection of Carbohydrate Antigen 19-9. Front Chem 2020;8:592445. [PMID: 33718326 DOI: 10.3389/fchem.2020.592445] [Reference Citation Analysis]
256 Di Agostino S. The Impact of Mutant p53 in the Non-Coding RNA World. Biomolecules 2020;10:E472. [PMID: 32204575 DOI: 10.3390/biom10030472] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
257 Li X, Xiao Y, Fan S, Xiao M, Wang X, Zhu X, Chen X, Li C, Zong G, Zhou G, Wan C. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. Human Pathology 2016;57:182-92. [DOI: 10.1016/j.humpath.2016.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
258 Bai H, Lei K, Huang F, Jiang Z, Zhou X. Exo-circRNAs: a new paradigm for anticancer therapy. Mol Cancer 2019;18:56. [PMID: 30925885 DOI: 10.1186/s12943-019-0986-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
259 Wu K, Wang W, Chen H, Gao W, Yu C. Insulin promotes proliferation of pancreatic ductal epithelial cells by increasing expression of PLK1 through PI3K/AKT and NF-κB pathway. Biochem Biophys Res Commun 2019;509:925-30. [PMID: 30642632 DOI: 10.1016/j.bbrc.2018.12.182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
260 Li J, Jin Q, Huang F, Tang Z, Huang J. Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells. Pancreas 2017;46:1173-9. [DOI: 10.1097/mpa.0000000000000910] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
261 Li MM, Cao J, Yang JC, Shen YJ, Cai XL, Chen YW, Qu CY, Zhang Y, Shen F, Xu LM. Effects of arginine-glycine-aspartic acid peptide-conjugated quantum dots-induced photodynamic therapy on pancreatic carcinoma in vivo. Int J Nanomedicine. 2017;12:2769-2779. [PMID: 28435257 DOI: 10.2147/ijn.s130799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
262 Arvaniti M, Danias N, Igoumenidis M, Smyrniotis V, Tsounis A, Sarafis P. Comparison of Quality of Life before and after pancreaticoduodenectomy: a prospective study. Electron Physician 2018;10:7054-62. [PMID: 30128096 DOI: 10.19082/7054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
263 Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C. Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells. Food Chem Toxicol 2021;147:111892. [PMID: 33271260 DOI: 10.1016/j.fct.2020.111892] [Reference Citation Analysis]
264 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol 2015; 21(11): 3157-3165 [PMID: 25805920 DOI: 10.3748/wjg.v21.i11.3157] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
265 He XY, Yuan YZ. Advances in pancreatic cancer research: Moving towards early detection. World J Gastroenterol 2014; 20(32): 11241-11248 [PMID: 25170208 DOI: 10.3748/wjg.v20.i32.11241] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
266 Turanli B, Yildirim E, Gulfidan G, Arga KY, Sinha R. Current State of "Omics" Biomarkers in Pancreatic Cancer. J Pers Med 2021;11:127. [PMID: 33672926 DOI: 10.3390/jpm11020127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
267 D'Agosto S, Andreani S, Scarpa A, Corbo V. Preclinical Modelling of PDA: Is Organoid the New Black? Int J Mol Sci 2019;20:E2766. [PMID: 31195689 DOI: 10.3390/ijms20112766] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
268 Gan H, Liu H, Zhang H, Li Y, Xu X, Xu X, Xu J. SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells. Tumour Biol 2016;37:9943-50. [PMID: 26815504 DOI: 10.1007/s13277-016-4898-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
269 Estrada-Martínez LE, Moreno-Celis U, Cervantes-Jiménez R, Ferriz-Martínez RA, Blanco-Labra A, García-Gasca T. Plant Lectins as Medical Tools against Digestive System Cancers. Int J Mol Sci 2017;18:E1403. [PMID: 28671623 DOI: 10.3390/ijms18071403] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
270 Olaoba OT, Ligali FC, Alabi ZO, Akinyemi AO, Ayinde KS. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. Biochim Biophys Acta Rev Cancer 2021;1875:188483. [PMID: 33232723 DOI: 10.1016/j.bbcan.2020.188483] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Changazi SH, Ahmed Q, Bhatti S, Siddique S, Abdul Raffay E, Farooka MW, Ayyaz M. Whipple Procedure: A Five-Year Clinical Experience in Tertiary Care Center. Cureus 2020;12:e11466. [PMID: 33329963 DOI: 10.7759/cureus.11466] [Reference Citation Analysis]
272 Gemenetzis G, Groot VP, Yu J, Ding D, Teinor JA, Javed AA, Wood LD, Burkhart RA, Cameron JL, Makary MA, Weiss MJ, He J, Wolfgang CL. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. Annals of Surgery 2018;268:408-20. [DOI: 10.1097/sla.0000000000002925] [Cited by in Crossref: 55] [Cited by in F6Publishing: 27] [Article Influence: 18.3] [Reference Citation Analysis]
273 Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 2016;1866:163-76. [PMID: 27567928 DOI: 10.1016/j.bbcan.2016.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
274 Dai L, Lu C, Yu XI, Dai LJ, Zhou JX. Construction of orthotopic xenograft mouse models for human pancreatic cancer. Exp Ther Med 2015;10:1033-8. [PMID: 26622435 DOI: 10.3892/etm.2015.2642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
275 Liu J, Huang Y, Liu Y, Chen Y. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway. Med Sci Monit 2019;25:6085-96. [PMID: 31412018 DOI: 10.12659/MSM.917625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
276 Gheorghe G, Bungau S, Ilie M, Behl T, Vesa CM, Brisc C, Bacalbasa N, Turi V, Costache RS, Diaconu CC. Early Diagnosis of Pancreatic Cancer: The Key for Survival. Diagnostics (Basel) 2020;10:E869. [PMID: 33114412 DOI: 10.3390/diagnostics10110869] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
277 Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Adv Ther 2018;35:1564-77. [PMID: 30209750 DOI: 10.1007/s12325-018-0784-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
278 Zhang LP, Ren H, Du YX, Zheng XH, Zhang ZM, Wang CF. Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastrointest Surg 2021; 13(3): 279-302 [PMID: 33796216 DOI: 10.4240/wjgs.v13.i3.279] [Reference Citation Analysis]
279 Wang S, Huang S, Sun YL. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. Biomed Res Int. 2017;2017:2646148. [PMID: 29379795 DOI: 10.1155/2017/2646148] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
280 Zhou X, Wang X, Duan J, Sun W, Chen Z, Li Q, Ou Z, Jiang G, Ren X, Liu S. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Pathology - Research and Practice 2019;215:343-6. [DOI: 10.1016/j.prp.2018.12.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
281 Aguirre AJ, Collisson EA. Advances in the Genetics and Biology of Pancreatic Cancer. Cancer J 2017;23:315-20. [PMID: 29189326 DOI: 10.1097/PPO.0000000000000286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
282 Gong C, Zhang Y, Chen Y, Zhang H, Liu X, Xue H, Ji L, Wang L, Yang L, Zhou G, Wan C. High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Tumour Biol 2015;36:9189-99. [PMID: 26088450 DOI: 10.1007/s13277-015-3625-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
283 Ma YS, Yang XL, Liu YS, Ding H, Wu JJ, Shi Y, Jia CY, Lu GX, Zhang DD, Wang HM, Wang PY, Yu F, Lv ZW, Wang GR, Liu JB, Fu D. Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition. J Transl Med 2021;19:400. [PMID: 34551785 DOI: 10.1186/s12967-021-03052-5] [Reference Citation Analysis]
284 Lin T, Ren Q, Zuo W, Jia R, Xie L, Lin R, Zhao H, Chen J, Lei Y, Wang P, Dong H, Huang L, Cai J, Peng Y, Yu Z, Tan J, Wang S. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Exp Clin Cancer Res 2019;38:150. [PMID: 30961642 DOI: 10.1186/s13046-019-1160-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
285 Kim MS, Zhong Y, Yachida S, Rajeshkumar NV, Abel ML, Marimuthu A, Mudgal K, Hruban RH, Poling JS, Tyner JW, Maitra A, Iacobuzio-Donahue CA, Pandey A. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Mol Cell Proteomics 2014;13:2803-11. [PMID: 24895378 DOI: 10.1074/mcp.M114.038547] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 6.1] [Reference Citation Analysis]
286 Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM. Statins and pancreatic cancer. Oncol Lett 2017;13:1035-40. [PMID: 28454210 DOI: 10.3892/ol.2017.5572] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
287 Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. World J Gastroenterol 2014; 20(38): 13987-13992 [PMID: 25320537 DOI: 10.3748/wjg.v20.i38.13987] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
288 Harada K, Murayama Y, Kubo H, Matsuo H, Morimura R, Ikoma H, Fujiwara H, Okamoto K, Tanaka T, Otsuji E. Photodynamic diagnosis of peritoneal metastasis in human pancreatic cancer using 5-aminolevulinic acid during staging laparoscopy. Oncol Lett 2018;16:821-8. [PMID: 29963150 DOI: 10.3892/ol.2018.8732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
289 N'Guessan KF, Davis HW, Chu Z, Vallabhapurapu SD, Lewis CS, Franco RS, Olowokure O, Ahmad SA, Yeh JJ, Bogdanov VY, Qi X. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Mol Ther. 2020;28:1876-1886. [PMID: 32516572 DOI: 10.1016/j.ymthe.2020.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
290 Jagadeeshan S, Subramanian A, Tentu S, Beesetti S, Singhal M, Raghavan S, Surabhi RP, Mavuluri J, Bhoopalan H, Biswal J. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer. Ann Oncol. 2016;27:1546-1556. [PMID: 27117533 DOI: 10.1093/annonc/mdw184] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
291 Yin X, Wang M, Wang H, Deng H, He T, Tan Y, Zhu Z, Wu Z, Hu S, Li Z. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids 2017;49:1325-35. [PMID: 28536844 DOI: 10.1007/s00726-017-2430-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
292 Morani AC, Hanafy AK, Ramani NS, Katabathina VS, Yedururi S, Dasyam AK, Prasad SR. Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging. Radiol Imaging Cancer 2020;2:e190020. [PMID: 33778702 DOI: 10.1148/rycan.2020190020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Han S, Qi Y, Luo Y, Chen X, Liang H. Exosomal Long Non-Coding RNA: Interaction Between Cancer Cells and Non-Cancer Cells. Front Oncol 2020;10:617837. [PMID: 33520726 DOI: 10.3389/fonc.2020.617837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Huang M, Xin W. Matrine inhibiting pancreatic cells epithelial-mesenchymal transition and invasion through ROS/NF-κB/MMPs pathway. Life Sci 2018;192:55-61. [PMID: 29155301 DOI: 10.1016/j.lfs.2017.11.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
295 Liu Q, Stewart J, Wang H, Rashid A, Zhao J, Katz MH, Lee JE, Fleming JB, Maitra A, Wolff RA, Varadhachary GR, Krishnan S, Wang H. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One 2017;12:e0171985. [PMID: 28187218 DOI: 10.1371/journal.pone.0171985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
296 Kitahata Y, Hirono S, Kawai M, Okada K, Miyazawa M, Shimizu A, Kobayashi R, Ueno M, Hayami S, Shimokawa T, Kouda K, Tajima F, Yamaue H. Intensive perioperative rehabilitation improves surgical outcomes after pancreaticoduodenectomy. Langenbecks Arch Surg 2018;403:711-8. [DOI: 10.1007/s00423-018-1710-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
297 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
298 Yang W, Reznik R, Fraass BA, Nissen N, Hendifar A, Wachsman A, Sandler H, Tuli R. Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Medical Dosimetry 2015;40:47-52. [DOI: 10.1016/j.meddos.2014.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
299 Chang ST, Jeffrey RB, Patel BN, Dimaio MA, Rosenberg J, Willmann JK, Olcott EW. Preoperative Multidetector CT Diagnosis of Extrapancreatic Perineural or Duodenal Invasion Is Associated with Reduced Postoperative Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Preliminary Experience and Implications for Patient Care. Radiology 2016;281:816-25. [DOI: 10.1148/radiol.2016152790] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
300 Grizzi F, Fiorino S, Qehajaj D, Fornelli A, Russo C, de Biase D, Masetti M, Mastrangelo L, Zanello M, Lombardi R, Domanico A, Accogli E, Tura A, Mirandola L, Chiriva-Internati M, Bresalier RS, Jovine E, Leandri P, Di Tommaso L. Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study. J Transl Med 2019;17:61. [PMID: 30819202 DOI: 10.1186/s12967-019-1817-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
301 Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L. Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. Oncotarget 2016;7:40148-59. [PMID: 27223086 DOI: 10.18632/oncotarget.9512] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
302 Ding D, Javed AA, Cunningham D, Teinor J, Wright M, Javed ZN, Wilt C, Parish L, Hodgin M, Ryan A, Judkins C, McIntyre K, Klein R, Azad N, Lee V, Donehower R, De Jesus-Acosta A, Murphy A, Le DT, Shin EJ, Lennon AM, Khashab M, Singh V, Klein AP, Roberts NJ, Hacker-Prietz A, Manos L, Walsh C, Groshek L, Brown C, Yuan C, Blair AB, Groot V, Gemenetzis G, Yu J, Weiss MJ, Burkhart RA, Burns WR, He J, Cameron JL, Narang A, Zaheer A, Fishman EK, Thompson ED, Anders R, Hruban RH, Jaffee E, Wolfgang CL, Zheng L, Laheru DA. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Cancer Lett 2021;497:221-8. [PMID: 33127389 DOI: 10.1016/j.canlet.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
303 Wu MY, Xie X, Xu ZK, Xie L, Chen Z, Shou LM, Gong FR, Xie YF, Li W, Tao M. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradation of β-catenin. Oncol Rep 2014;32:513-22. [PMID: 24926961 DOI: 10.3892/or.2014.3266] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
304 Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, Filliol A, Chin L, Savage TM, Yin D, Wirsik NM, Mehal A, Arpaia N, Seki E, Mack M, Zhu D, Sims PA, Kalluri R, Stanger BZ, Olive KP, Schmidt T, Wells RG, Mederacke I, Schwabe RF. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest 2021;131:146987. [PMID: 33905375 DOI: 10.1172/JCI146987] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
305 Ross KC, Andrews AJ, Marion CD, Yen TJ, Bhattacharjee V. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells. Mol Cancer Ther 2017;16:1596-609. [PMID: 28500236 DOI: 10.1158/1535-7163.MCT-16-0798] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
306 Kovač U, Skubic C, Bohinc L, Rozman D, Režen T. Oxysterols and Gastrointestinal Cancers Around the Clock. Front Endocrinol (Lausanne) 2019;10:483. [PMID: 31379749 DOI: 10.3389/fendo.2019.00483] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
307 Shen Y, Chen G, Zhuang L, Xu L, Lin J, Liu L. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. Onco Targets Ther 2019;12:5003-12. [PMID: 31303760 DOI: 10.2147/OTT.S207560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
308 Lohse I, Brothers SP. Pathogenesis and Treatment of Pancreatic Cancer Related Pain. Anticancer Res 2020;40:1789-96. [PMID: 32234867 DOI: 10.21873/anticanres.14133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
309 Weledji EP, Enoworock G, Mokake M, Sinju M. How Grim is Pancreatic Cancer? Oncol Rev 2016;10:294. [PMID: 27471581 DOI: 10.4081/oncol.2016.294] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
310 Liu F, Le W, Mei T, Wang T, Chen L, Lei Y, Cui S, Chen B, Cui Z, Shao C. In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody. Int J Nanomedicine 2016;11:2195-207. [PMID: 27274243 DOI: 10.2147/IJN.S104501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
311 Li HY, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. Tumour Biol. 2015;36:1375-1384. [PMID: 25680410 DOI: 10.1007/s13277-015-3223-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
312 Campa D, Rizzato C, Stolzenberg-Solomon R, Pacetti P, Vodicka P, Cleary SP, Capurso G, Bueno-de-Mesquita HB, Werner J, Gazouli M, Butterbach K, Ivanauskas A, Giese N, Petersen GM, Fogar P, Wang Z, Bassi C, Ryska M, Theodoropoulos GE, Kooperberg C, Li D, Greenhalf W, Pasquali C, Hackert T, Fuchs CS, Mohelnikova-Duchonova B, Sperti C, Funel N, Dieffenbach AK, Wareham NJ, Buring J, Holcátová I, Costello E, Zambon CF, Kupcinskas J, Risch HA, Kraft P, Bracci PM, Pezzilli R, Olson SH, Sesso HD, Hartge P, Strobel O, Małecka-Panas E, Visvanathan K, Arslan AA, Pedrazzoli S, Souček P, Gioffreda D, Key TJ, Talar-Wojnarowska R, Scarpa A, Mambrini A, Jacobs EJ, Jamroziak K, Klein A, Tavano F, Bambi F, Landi S, Austin MA, Vodickova L, Brenner H, Chanock SJ, Delle Fave G, Piepoli A, Cantore M, Zheng W, Wolpin BM, Amundadottir LT, Canzian F. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Int J Cancer 2015;137:2175-83. [PMID: 25940397 DOI: 10.1002/ijc.29590] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
313 Wang L, Zhou W, Zhong Y, Huo Y, Fan P, Zhan S, Xiao J, Jin X, Gou S, Yin T, Wu H, Liu T. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway. Mol Cancer 2017;16:61. [PMID: 28288630 DOI: 10.1186/s12943-017-0627-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
314 Wang Y, Li Z, Xu S, Guo J. Novel potential tumor biomarkers: Circular RNAs and exosomal circular RNAs in gastrointestinal malignancies. J Clin Lab Anal 2020;34:e23359. [PMID: 32419229 DOI: 10.1002/jcla.23359] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
315 Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Oncol Lett 2018;16:2682-92. [PMID: 30008944 DOI: 10.3892/ol.2018.8961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
316 Wei L, Ye H, Li G, Lu Y, Zhou Q, Zheng S, Lin Q, Liu Y, Li Z, Chen R. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death Dis 2018;9:1065. [PMID: 30337520 DOI: 10.1038/s41419-018-1104-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 49] [Article Influence: 11.7] [Reference Citation Analysis]
317 Zhu J, Ji Y, Yu Y, Jin Y, Zhang X, Zhou J, Chen Y. Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro. Oncol Lett 2018;15:8761-9. [PMID: 29805615 DOI: 10.3892/ol.2018.8363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
318 Jin W, Yin H, Li H, Yu XJ, Xu HX, Liu L. Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway. J Cell Mol Med 2021;25:5443-56. [PMID: 33955688 DOI: 10.1111/jcmm.16555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
319 Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202-213. [PMID: 31158393 DOI: 10.1016/j.pharmthera.2019.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
320 Li X, Zhu F, Jiang J, Sun C, Zhong Q, Shen M, Wang X, Tian R, Shi C, Xu M, Peng F, Guo X, Hu J, Ye D, Wang M, Qin R. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Autophagy 2016;12:1521-37. [PMID: 27308733 DOI: 10.1080/15548627.2016.1191722] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
321 Fendrich V, Lauth M. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. Expert Opin Ther Targets 2014;18:1277-83. [PMID: 25078025 DOI: 10.1517/14728222.2014.945427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
322 Jia R, Zhao H, Wang S. Neuregulin Signaling in the Tumor Microenvironment. Adv Exp Med Biol 2021;1270:1-29. [PMID: 33123990 DOI: 10.1007/978-3-030-47189-7_1] [Reference Citation Analysis]
323 Li Z, Jiang P, Li J, Peng M, Zhao X, Zhang X, Chen K, Zhang Y, Liu H, Gan L, Bi H, Zhen P, Zhu J, Li X. Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma. Oncogene 2018;37:3822-38. [PMID: 29643475 DOI: 10.1038/s41388-018-0237-9] [Cited by in Crossref: 104] [Cited by in F6Publishing: 114] [Article Influence: 34.7] [Reference Citation Analysis]
324 Chen Q, Yu D, Zhao Y, Qiu J, Xie Y, Tao M. Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis. J Cell Biochem 2019;120:19496-508. [PMID: 31297881 DOI: 10.1002/jcb.29253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
325 Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1-10. [PMID: 29564165 DOI: 10.21037/jgo.2017.10.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
326 Gao Y, Zhu Y, Yuan Z. Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. Int J Med Sci 2016;13:902-13. [PMID: 27994495 DOI: 10.7150/ijms.16734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
327 Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS, Richardson DR. Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget 2015;6:18748-79. [PMID: 26125440 DOI: 10.18632/oncotarget.4349] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 19.2] [Reference Citation Analysis]
328 Wu L, Guo W, Li Y, Cheng T, Yao Y, Zhang Y, Liu B, Zhong M, Li S, Deng X, Zhu W. [Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma]. Nan Fang Yi Ke Da Xue Xue Bao. 2018;38:1171-1178. [PMID: 30377133 DOI: 10.3969/j.issn.1673-4254.2018.10.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
329 Erdek MA, King LM, Ellsworth SG. Pain management and palliative care in pancreatic cancer. Curr Probl Cancer. 2013;37:266-272. [PMID: 24331181 DOI: 10.1016/j.currproblcancer.2013.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
330 Xie S, Wu Y, Hao H, Li J, Guo S, Xie W, Li D, Zhou J, Gao J, Liu M. CYLD deficiency promotes pancreatic cancer development by causing mitotic defects. J Cell Physiol 2019;234:9723-32. [PMID: 30362575 DOI: 10.1002/jcp.27658] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
331 Kim VM, Ahuja N. Early detection of pancreatic cancer. Chin J Cancer Res 2015;27:321-31. [PMID: 26361402 DOI: 10.3978/j.issn.1000-9604.2015.07.03] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
332 Felix K, Hinz U, Dobiasch S, Hackert T, Bergmann F, Neumüller M, Gronowitz S, Bergqvist M, Strobel O. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer. Pancreas 2018;47:72-9. [PMID: 29189449 DOI: 10.1097/MPA.0000000000000966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
333 Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 2016;4:315-25. [PMID: 26998283 DOI: 10.3892/mco.2015.716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
334 Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Int J Mol Sci 2016;17:E1090. [PMID: 27399694 DOI: 10.3390/ijms17071090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
335 Ma L, Tian X, Wang F, Zhang Z, Du C, Xie X, Kornmann M, Yang Y. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2016;17:1051-61. [PMID: 27573434 DOI: 10.1080/15384047.2016.1219814] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
336 Ma H, Liu ZX, Zhang JJ, Wu FT, Xu CF, Shen Z, Yu CH, Li YM. Construction of a convolutional neural network classifier developed by computed tomography images for pancreatic cancer diagnosis. World J Gastroenterol 2020; 26(34): 5156-5168 [PMID: 32982116 DOI: 10.3748/wjg.v26.i34.5156] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
337 Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, Liang T. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Mol Cancer 2017;16:119. [PMID: 28705232 DOI: 10.1186/s12943-017-0689-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
338 Peng W, Zhang J, Liu J. URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. Med Oncol 2014;31:64. [PMID: 24930007 DOI: 10.1007/s12032-014-0064-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
339 Liang J, Yang Y, Bai L, Li F, Li E. DRP1 upregulation promotes pancreatic cancer growth and metastasis through increased aerobic glycolysis. Journal of Gastroenterology and Hepatology 2020;35:885-95. [DOI: 10.1111/jgh.14912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
340 Chen S, Chen JZ, Zhang JQ, Chen HX, Yan ML, Huang L, Tian YF, Chen YL, Wang YD. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. Cancer Lett. 2016;383:73-84. [PMID: 27693633 DOI: 10.1016/j.canlet.2016.09.027] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
341 Khan T, Seddon AM, Dalgleish AG, Khelwatty S, Ioannou N, Mudan S, Modjtahedi H. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. Oncol Rep 2020;44:2581-94. [PMID: 33125153 DOI: 10.3892/or.2020.7822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
342 Zhang H, Zhang X, Li X, Meng WB, Bai ZT, Rui SZ, Wang ZF, Zhou WC, Jin XD. Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J Cell Physiol. 2018;234:619-631. [PMID: 30069972 DOI: 10.1002/jcp.26816] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
343 Shen Y, Xu L, Ning Z, Liu L, Lin J, Chen H, Meng Z. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Carcinogenesis 2019;40:1405-14. [DOI: 10.1093/carcin/bgz067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
344 Tao SC, Guo SC. Role of extracellular vesicles in tumour microenvironment. Cell Commun Signal 2020;18:163. [PMID: 33081785 DOI: 10.1186/s12964-020-00643-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
345 Naguib YW, Lansakara-P D, Lashinger LM, Rodriguez BL, Valdes S, Niu M, Aldayel AM, Peng L, Hursting SD, Cui Z. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity. Neoplasia 2016;18:33-48. [PMID: 26806350 DOI: 10.1016/j.neo.2015.11.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
346 Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016;381:244-251. [PMID: 26723878 DOI: 10.1016/j.canlet.2015.12.020] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 15.0] [Reference Citation Analysis]
347 Rong Q, Feng F, Ma Z. Metal ions doped chitosan–poly(acrylic acid) nanospheres: Synthesis and their application in simultaneously electrochemical detection of four markers of pancreatic cancer. Biosensors and Bioelectronics 2016;75:148-54. [DOI: 10.1016/j.bios.2015.08.041] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
348 Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, Zhu Q, Eshleman JR, Anders RA, Jaffee EM, Fujiwara K, Zheng L. Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. Gastroenterology 2019;157:838-850.e6. [PMID: 31163177 DOI: 10.1053/j.gastro.2019.05.065] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
349 Pei Y, Chen L, Huang Y, Wang J, Feng J, Xu M, Chen Y, Song Q, Jiang G, Gu X, Zhang Q, Gao X, Chen J. Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. Small 2019;15:1900631. [DOI: 10.1002/smll.201900631] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
350 Lu H, Ren Z, Li A, Li J, Xu S, Zhang H, Jiang J, Yang J, Luo Q, Zhou K, Zheng S, Li L. Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J Oral Microbiol 2019;11:1563409. [PMID: 30728915 DOI: 10.1080/20002297.2018.1563409] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
351 Chen Y, Bai X, Zhang Q, Wen L, Su W, Fu Q, Sun X, Lou Y, Yang J, Zhang J, Chen Q, Wang J, Liang T. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. Cancer Letters 2016;380:98-105. [DOI: 10.1016/j.canlet.2016.06.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
352 Liu Y, Jin ZR, Huang X, Che YC, Liu Q. Identification of Spindle and Kinetochore-Associated Family Genes as Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment. Front Oncol 2020;10:553536. [PMID: 33224872 DOI: 10.3389/fonc.2020.553536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
353 Liu Q, Li Y, Yao L. Knockdown of AGR2 induces cell apoptosis and reduces chemotherapy resistance of pancreatic cancer cells with the involvement of ERK/AKT axis. Pancreatology 2018;18:678-88. [DOI: 10.1016/j.pan.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
354 Han Y, Ma L, Zhao L, Feng W, Zheng X. Rosmarinic inhibits cell proliferation, invasion and migration via up-regulating miR-506 and suppressing MMP2/16 expression in pancreatic cancer. Biomedicine & Pharmacotherapy 2019;115:108878. [DOI: 10.1016/j.biopha.2019.108878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
355 Mahalingam D, Wilkinson GA, Eng KH, Fields P, Raber P, Moseley JL, Cheetham K, Coffey M, Nuovo G, Kalinski P, Zhang B, Arora SP, Fountzilas C. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clin Cancer Res 2020;26:71-81. [PMID: 31694832 DOI: 10.1158/1078-0432.CCR-19-2078] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
356 Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229669 DOI: 10.1101/cshperspect.a031435] [Cited by in Crossref: 201] [Cited by in F6Publishing: 198] [Article Influence: 67.0] [Reference Citation Analysis]
357 Zhu HY, Gao YJ, Wang Y, Liang C, Zhang ZX, Chen Y. LncRNA CRNDE promotes the progression and angiogenesis of pancreatic cancer via miR-451a/CDKN2D axis. Transl Oncol 2021;14:101088. [PMID: 33882369 DOI: 10.1016/j.tranon.2021.101088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
359 Ke J, Peng X, Mei S, Tian J, Ying P, Yang N, Wang X, Zou D, Yang Y, Zhu Y, Gong Y, Gong J, Zhong R, Chang J, Fang Z, Miao X. Evaluation of polymorphisms in microRNA-binding sites and pancreatic cancer risk in Chinese population. J Cell Mol Med 2020;24:2252-9. [PMID: 31880394 DOI: 10.1111/jcmm.14906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
360 Peng T, Zhou W, Guo F, Wu HS, Wang CY, Wang L, Yang ZY. Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness. Sci Rep 2017;7:5925. [PMID: 28724890 DOI: 10.1038/s41598-017-06132-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
361 Zhang C, Huang L, Xiong J, Xie L, Ying S, Jia Y, Yao Y, Song X, Zeng Z, Yuan J. Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway. PLoS One 2021;16:e0247752. [PMID: 33661942 DOI: 10.1371/journal.pone.0247752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
362 Zhang M, Ding G, Zhou L, Shen T, Xu X, Zhao T, Jia S, Cao L. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. J Interferon Cytokine Res 2018;38:413-22. [PMID: 30192158 DOI: 10.1089/jir.2018.0070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
363 Guo X, Ling X, Du F, Wang Q, Huang W, Wang Z, Ding X, Bai M, Wu Z. Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe. Transl Oncol 2018;11:1065-73. [PMID: 30005208 DOI: 10.1016/j.tranon.2018.06.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
364 Roy S, Singh AP, Gupta D. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma. Heliyon 2021;7:e06000. [PMID: 33521362 DOI: 10.1016/j.heliyon.2021.e06000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
365 Søreide K, Sund M. Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. Cancer Lett 2015;356:281-8. [PMID: 24704294 DOI: 10.1016/j.canlet.2014.03.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
366 Li C, Zeng X, Yu H, Gu Y, Zhang W. Identification of hub genes with diagnostic values in pancreatic cancer by bioinformatics analyses and supervised learning methods. World J Surg Oncol 2018;16:223. [PMID: 30428899 DOI: 10.1186/s12957-018-1519-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
367 Bai X, Zhi X, Zhang Q, Liang F, Chen W, Liang C, Hu Q, Sun X, Zhuang Z, Liang T. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett 2014;355:281-7. [PMID: 25304380 DOI: 10.1016/j.canlet.2014.09.048] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
368 Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer 2020;19:32. [PMID: 32061257 DOI: 10.1186/s12943-020-01151-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 21.0] [Reference Citation Analysis]
369 Chen Q, Wang WJ, Jia YX, Yuan H, Wu PF, Ge WL, Meng LD, Huang XM, Shen P, Yang TY, Miao Y, Zhang JJ, Jiang KR. Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell Biosci 2021;11:86. [PMID: 33985581 DOI: 10.1186/s13578-021-00602-8] [Reference Citation Analysis]
370 Kong F, Liu X, Zhou Y, Hou X, He J, Li Q, Miao X, Yang L. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol 2020;122:105731. [PMID: 32097728 DOI: 10.1016/j.biocel.2020.105731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
371 Rosati LM, Kumar R, Herman JM. Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer. Semin Radiat Oncol 2017;27:256-67. [PMID: 28577833 DOI: 10.1016/j.semradonc.2017.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
372 Bosch X, Moreno P, Guerra-García M, Guasch N, López-Soto A. What is the relevance of an ambulatory quick diagnosis unit or inpatient admission for the diagnosis of pancreatic cancer? A retrospective study of 1004 patients. Medicine (Baltimore) 2020;99:e19009. [PMID: 32176029 DOI: 10.1097/MD.0000000000019009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
373 Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol 2016;6:99. [PMID: 27200288 DOI: 10.3389/fonc.2016.00099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
374 Schöffel N, Krempel M, Bundschuh M, Bendels MH, Brüggmann D, Groneberg DA. Pancreatic Cancer-Critical Examination of the Global Research Architecture and Recent Scientific Developments. Pancreas 2016;45:1378-85. [PMID: 27518470 DOI: 10.1097/MPA.0000000000000693] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
375 Welinsky S, Lucas AL. Familial Pancreatic Cancer and the Future of Directed Screening. Gut Liver 2017;11:761-70. [PMID: 28609837 DOI: 10.5009/gnl16414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
376 He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, Weiss MJ, Cameron JL, Wolfgang CL. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Ann Surg. 2018;268:1-8. [PMID: 29334562 DOI: 10.1097/sla.0000000000002672] [Cited by in Crossref: 75] [Cited by in F6Publishing: 31] [Article Influence: 37.5] [Reference Citation Analysis]
377 Aghamiri S, Raee P, Talaei S, Mohammadi-Yeganeh S, Bayat S, Rezaee D, Ghavidel AA, Teymouri A, Roshanzamiri S, Farhadi S, Ghanbarian H. Nonviral siRNA delivery systems for pancreatic cancer therapy. Biotechnol Bioeng 2021. [PMID: 34170520 DOI: 10.1002/bit.27869] [Reference Citation Analysis]
378 Wright MJ, Javed AA, Saunders T, Zhu Y, Burkhart RA, Yu J, He J, Cameron JL, Makary MA, Wolfgang CL, Weiss MJ. Surgical Resection of 78 Pancreatic Solid Pseudopapillary Tumors: a 30-Year Single Institutional Experience. J Gastrointest Surg. 2020;24:874-881. [PMID: 31073801 DOI: 10.1007/s11605-019-04252-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
379 Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget 2015;6:36903-10. [PMID: 26372811 DOI: 10.18632/oncotarget.5054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
380 Guo Z, Wang F, Di Y, Yao L, Yu X, Fu D, Li J, Jin C. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. Int J Nanomedicine 2018;13:4869-80. [PMID: 30214194 DOI: 10.2147/IJN.S166769] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
381 Zhai H, Zhang X, Sun X, Zhang D, Ma S. Long Non-coding RNA LINC01420 Contributes to Pancreatic Cancer Progression Through Targeting KRAS Proto-oncogene. Dig Dis Sci 2020;65:1042-52. [PMID: 31562613 DOI: 10.1007/s10620-019-05829-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
382 Xia P, Liu P, Fu Q, Liu C, Luo Q, Zhang X, Cheng L, Qin T, Zhang H. Long noncoding RNA EPIC1 interacts with YAP1 to regulate the cell cycle and promote the growth of pancreatic cancer cells. Biochemical and Biophysical Research Communications 2020;522:978-85. [DOI: 10.1016/j.bbrc.2019.11.167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
383 Arvaniti M, Danias N, Theodosopoulou E, Smyrniotis V, Karaoglou M, Sarafis P. Quality of Life Variables Assessment, Before and After Pancreatoduodenectomy (PD): Prospective Study. Glob J Health Sci 2015;8:203-10. [PMID: 26755486 DOI: 10.5539/gjhs.v8n6p203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
384 Kinoshita H, Kanda T, Takata T, Sugihara T, Mae Y, Yamashita T, Onoyama T, Takeda Y, Isomoto H. Oligopeptide Transporter-1 is Associated with Fluorescence Intensity of 5-Aminolevulinic Acid-Based Photodynamic Diagnosis in Pancreatic Cancer Cells. Yonago Acta Med 2020;63:154-62. [PMID: 32884434 DOI: 10.33160/yam.2020.08.003] [Reference Citation Analysis]
385 Shen CQ, Yan TT, Liu W, Zhu XQ, Tian XL, Fu XL, Hua R, Zhang JF, Huo YM, Liu DJ, Yang JY, Sun YW, Fang JY, Chen HY, Hong J. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. J Cancer 2017;8:3154-65. [PMID: 29158787 DOI: 10.7150/jca.20086] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
386 Wang X, Wu X, Zhang Z, Ma C, Wu T, Tang S, Zeng Z, Huang S, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Shen Y, Luo W, Wang X, Liu B, Lei Y, Ye Z, Zhao L, Cao D, Yang L, Chen X, Haydon RC, Luu HH, Peng B, Liu X, He TC. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 2018;8:17914. [PMID: 30559409 DOI: 10.1038/s41598-018-36214-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
387 Chen Q, Wang J, Chen W, Zhang Q, Wei T, Zhou Y, Xu X, Bai X, Liang T. B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. Cancer Sci 2019;110:530-9. [PMID: 30548441 DOI: 10.1111/cas.13914] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
388 Mattheolabakis G, Papayannis I, Yang J, Vaeth BM, Wang R, Bandovic J, Ouyang N, Rigas B, Mackenzie GG. Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice. Cancer Prev Res (Phila) 2016;9:624-34. [PMID: 27138793 DOI: 10.1158/1940-6207.CAPR-15-0344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
389 Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clin Cancer Res 2019;25:4973-84. [PMID: 31142500 DOI: 10.1158/1078-0432.CCR-19-0197] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
390 Yoo HJ, You MW, Han DY, Hwang JH, Park SJ. Tumor conspicuity significantly correlates with postoperative recurrence in patients with pancreatic cancer: a retrospective observational study. Cancer Imaging 2020;20:46. [PMID: 32650842 DOI: 10.1186/s40644-020-00321-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
391 Wang J, Zhang S, Wu J, Lu Z, Yang J, Wu H, Chen H, Lin B, Cao T. Clinical significance and prognostic value of SOX7 expression in liver and pancreatic carcinoma. Mol Med Rep 2017;16:499-506. [PMID: 28586005 DOI: 10.3892/mmr.2017.6660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
392 Krishnan M, Ahmed A, Walters RW, Silberstein PT. Factors Affecting Adjuvant Therapy in Stage III Pancreatic Cancer-Analysis of the National Cancer Database. Clin Med Insights Oncol 2017;11:1179554917728040. [PMID: 28894395 DOI: 10.1177/1179554917728040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
393 Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, Gong S, Zhu Y. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMedicine 2019;40:382-93. [PMID: 30639415 DOI: 10.1016/j.ebiom.2019.01.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
394 Li Z, Yu X, Werner J, Bazhin AV, D'Haese JG. The role of interleukin-18 in pancreatitis and pancreatic cancer. Cytokine Growth Factor Rev 2019;50:1-12. [PMID: 31753718 DOI: 10.1016/j.cytogfr.2019.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
395 Luongo M, Marinelli O, Zeppa L, Aguzzi C, Morelli MB, Amantini C, Frassineti A, di Costanzo M, Fanelli A, Santoni G, Nabissi M. Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel) 2020;12:E2774. [PMID: 32992648 DOI: 10.3390/cancers12102774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Zhang L, Lu L, Summers RM, Kebebew E, Yao J. Convolutional Invasion and Expansion Networks for Tumor Growth Prediction. IEEE Trans Med Imaging. 2018;37:638-648. [PMID: 29408791 DOI: 10.1109/tmi.2017.2774044] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 14.5] [Reference Citation Analysis]
397 Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH, Cameron JL, Weiss MJ, Wolfgang CL, Herman JM, He J. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery. 2018;163:1090-1096. [PMID: 29395234 DOI: 10.1016/j.surg.2017.11.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
398 Probst EA, Smith AL, Abad JD. What is causing this patient's severe pruritus? JAAPA 2020;33:54-6. [PMID: 32452965 DOI: 10.1097/01.JAA.0000662428.39636.70] [Reference Citation Analysis]
399 Wan C, Gong C, Ji L, Liu X, Wang Y, Wang L, Shao M, Yang L, Fan S, Xiao Y, Wang X, Li M, Zhou G, Zhang Y. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Mol Cell Biochem 2015;410:25-35. [PMID: 26276310 DOI: 10.1007/s11010-015-2535-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
400 Kuhlmann L, Nadler WM, Kerner A, Hanke SA, Noll EM, Eisen C, Espinet E, Vogel V, Trumpp A, Sprick MR, Roesli CP. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Pancreas 2017;46:311-22. [DOI: 10.1097/mpa.0000000000000743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
401 Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, Bulfamante S, Chapelle J, Di Modugno F, Defilippi P, Nisticò P, Cappello P, Riganti C, Leporatti S, Novelli F. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol 2017;10:16. [PMID: 28086938 DOI: 10.1186/s13045-016-0385-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
402 Tanaka M, Heckler M, Mihaljevic AL, Sun H, Klaiber U, Heger U, Büchler MW, Hackert T. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol 2019;45:1453-9. [PMID: 30981446 DOI: 10.1016/j.ejso.2019.03.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
403 Oba A, Inoue Y, Ono Y, Irie S, Sato T, Mise Y, Ito H, Takahashi Y, Saiura A. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Langenbecks Arch Surg 2020;405:35-41. [DOI: 10.1007/s00423-019-01846-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
404 Fokas E, O’Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochim Biophys Acta. 2015;1855:61-82. [PMID: 25489989 DOI: 10.1016/j.bbcan.2014.12.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
405 Chan MY, Chok KSH. Sarcopenia in pancreatic cancer – effects on surgical outcomes and chemotherapy. World J Gastrointest Oncol 2019; 11(7): 527-537 [PMID: 31367272 DOI: 10.4251/wjgo.v11.i7.527] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
406 Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014;2014:678401. [PMID: 25250326 DOI: 10.1155/2014/678401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
407 Natale F, Vivo M, Falco G, Angrisano T. Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis. Clin Epigenetics. 2019;11:132. [PMID: 31492175 DOI: 10.1186/s13148-019-0728-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
408 Kato T, Ban D, Tateishi U, Ogura T, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Reticular pattern around superior mesenteric artery in computed tomography imaging predicting poor prognosis of pancreatic head cancer. J Hepatobiliary Pancreat Sci 2020;27:114-23. [PMID: 31702106 DOI: 10.1002/jhbp.700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
409 Zhang Y, Zhang XX, Yuan RY, Ren T, Shao ZY, Wang HF, Cai WL, Chen LT, Wang XA, Wang P. Cordycepin induces apoptosis in human pancreatic cancer cells via the mitochondrial-mediated intrinsic pathway and suppresses tumor growth in vivo. Onco Targets Ther 2018;11:4479-90. [PMID: 30122940 DOI: 10.2147/OTT.S164670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
410 Cao Z, Liu C, Xu J, You L, Wang C, Lou W, Sun B, Miao Y, Liu X, Wang X, Zhang T, Zhao Y. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget. 2016;7:41575-41583. [PMID: 27223429 DOI: 10.18632/oncotarget.9491] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
411 Nishida T, Yoshitomi H, Takano S, Kagawa S, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Miyazaki M. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Pancreas 2016;45:593-600. [PMID: 26495781 DOI: 10.1097/MPA.0000000000000499] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
412 王刚, 李宗倍, 曲凤智, 孙备. 胰头癌R0切除时手术切缘的界定及影响因素. 世界华人消化杂志 2016; 24(9): 1315-1320 [DOI: 10.11569/wcjd.v24.i9.1315] [Reference Citation Analysis]
413 Sadr-azodi O, Gudbjörnsdottir S, Ljung R. Pattern of increasing HbA 1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer – a population-based nationwide case-control study. Acta Oncologica 2015;54:986-92. [DOI: 10.3109/0284186x.2015.1006402] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
414 Guo Y, Zhu H, Weng M, Wang C, Sun L. Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. BMC Complement Med Ther 2020;20:178. [PMID: 32513155 DOI: 10.1186/s12906-020-02976-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
415 Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL. Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol 2015;388:623-34. [PMID: 25743573 DOI: 10.1007/s00210-015-1107-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
416 He X, Zhong J, Wang S, Zhou Y, Wang L, Zhang Y, Yuan Y. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes. Oncotarget. 2017;8:29116-29124. [PMID: 28418859 DOI: 10.18632/oncotarget.16249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
417 Zhao Z, Shen X, Zhang D, Xiao H, Kong H, Yang B, Yang L. miR-153 enhances the therapeutic effect of radiotherapy by targeting JAG1 in pancreatic cancer cells. Oncol Lett 2021;21:300. [PMID: 33732376 DOI: 10.3892/ol.2021.12561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
418 Zhu B, Zhu Y, Lou J, Ke J, Zhang Y, Li J, Gong Y, Yang Y, Tian J, Peng X, Zou D, Zhong R, Gong J, Chang J, Li L, Miao X. A single nucleotide polymorphism in the 3'-UTR of STAT3 regulates its expression and reduces risk of pancreatic cancer in a Chinese population. Oncotarget 2016;7:62305-11. [PMID: 27577070 DOI: 10.18632/oncotarget.11607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
419 Anand S, Khan MA, Khushman M, Dasgupta S, Singh S, Singh AP. Comprehensive Analysis of Expression, Clinicopathological Association and Potential Prognostic Significance of RABs in Pancreatic Cancer. Int J Mol Sci 2020;21:E5580. [PMID: 32759795 DOI: 10.3390/ijms21155580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
420 Ye LY, Zhang Q, Bai XL, Pankaj P, Hu QD, Liang TB. Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. Pancreatology. 2014;14:391-397. [PMID: 25278309 DOI: 10.1016/j.pan.2014.06.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
421 Brauswetter D, Gurbi B, Varga A, Várkondi E, Schwab R, Bánhegyi G, Fábián O, Kéri G, Vályi-Nagy I, Peták I. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. PLoS One 2017;12:e0185687. [PMID: 28957417 DOI: 10.1371/journal.pone.0185687] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
422 Harricharran T, Ogunwobi OO. Oxytocin and oxytocin receptor alterations, decreased survival, and increased chemoresistance in patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 2020;19:175-80. [PMID: 31919036 DOI: 10.1016/j.hbpd.2019.12.002] [Reference Citation Analysis]
423 Zhou J, Qie S, Fang H, Xi J. MiR-487a-3p suppresses the malignant development of pancreatic cancer by targeting SMAD7. Exp Mol Pathol 2020;116:104489. [PMID: 32622014 DOI: 10.1016/j.yexmp.2020.104489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
424 Li T, Liu Q, Zhang R, Liao Q, Zhao Y. Identification of prognosis-related genes and construction of multi-regulatory networks in pancreatic cancer microenvironment by bioinformatics analysis. Cancer Cell Int 2020;20:341. [PMID: 32724299 DOI: 10.1186/s12935-020-01426-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
425 Saha S, Xiong X, Chakraborty PK, Shameer K, Arvizo RR, Kudgus RA, Dwivedi SK, Hossen MN, Gillies EM, Robertson JD, Dudley JT, Urrutia RA, Postier RG, Bhattacharya R, Mukherjee P. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano 2016;10:10636-51. [PMID: 27758098 DOI: 10.1021/acsnano.6b02231] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 15.6] [Reference Citation Analysis]
426 Zhang X, Zhang J, Fan H, Liu Y, He Q. Risk factors related to metastasis of para-aortic lymph nodes in pancreatic ductal adenocarcinoma: A retrospective observational study. Medicine (Baltimore) 2018;97:e12370. [PMID: 30290595 DOI: 10.1097/MD.0000000000012370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
427 Hang C, Gong C, Fang Y, Chen L, Zhu J. Ubiquitin-specific protease 14 (USP14) promotes proliferation and metastasis in pancreatic ductal adenocarcinoma. J Mol Histol 2021;52:187-96. [PMID: 33394290 DOI: 10.1007/s10735-020-09934-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
428 Franke AJ, Rosati LM, Pawlik TM, Kumar R, Herman JM. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. Semin Oncol. 2015;42:144-162. [PMID: 25726059 DOI: 10.1053/j.seminoncol.2014.12.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
429 Zhang Y, Chen D, Zhang G, Wu X, Zhou L, Lin Y, Ding J, An F, Zhan Q. MicroRNA-23b-3p promotes pancreatic cancer cell tumorigenesis and metastasis via the JAK/PI3K and Akt/NF-κB signaling pathways. Oncol Lett 2020;20:160. [PMID: 32934728 DOI: 10.3892/ol.2020.12021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Liu X, Huang Y, Yuan H, Qi X, Manjunath Y, Avella D, Kaifi JT, Miao Y, Li M, Jiang K, Li G. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Cancer Lett 2019;454:204-14. [PMID: 31004701 DOI: 10.1016/j.canlet.2019.04.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
431 Belbekhouche S, Cossutta M, Habert D, Hamadi S, Modjinou T, Cascone I, Courty J. N6L-functionalized nanoparticles for targeted and inhibited pancreatic cancer cells. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2020;607:125461. [DOI: 10.1016/j.colsurfa.2020.125461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
432 Kawano T, Murata M, Kang J, Piao JS, Narahara S, Hyodo F, Hamano N, Guo J, Oguri S, Ohuchida K, Hashizume M. Ultrasensitive MRI detection of spontaneous pancreatic tumors with nanocage-based targeted contrast agent. Biomaterials 2018;152:37-46. [DOI: 10.1016/j.biomaterials.2017.10.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
433 Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB 2017;19:83-92. [DOI: 10.1016/j.hpb.2016.11.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
434 Zhang X, Huang HJ, Feng D, Yang DJ, Wang CM, Cai QP. Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer? World J Gastroenterol 2014; 20(46): 17648-17655 [PMID: 25516680 DOI: 10.3748/wjg.v20.i46.17648] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
435 Liao X, Han C, Wang X, Huang K, Yu T, Yang C, Huang R, Liu Z, Han Q, Peng T. Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy. Cancer Manag Res 2018;10:3255-71. [PMID: 30233242 DOI: 10.2147/CMAR.S171293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
436 Zhao XH, Wang ZR, Chen CL, Di L, Bi ZF, Li ZH, Liu YM. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice. World J Gastroenterol 2019; 25(1): 138-150 [PMID: 30643364 DOI: 10.3748/wjg.v25.i1.138] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
437 Zhao X, Zhang Q, Wang Y, Li S, Yu X, Wang B, Wang X. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann Transl Med 2021;9:1084. [PMID: 34422996 DOI: 10.21037/atm-21-2630] [Reference Citation Analysis]
438 Xu Y, Li Z, Jiang P, Wu G, Chen K, Zhang X, Li X. The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer. Diagn Pathol. 2015;10:211. [PMID: 26652622 DOI: 10.1186/s13000-015-0445-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
439 Xue F, Song X, Zhang S, Niu M, Cui Y, Wang Y, Zhao T. Long non-coding RNA TMPO-AS1 serves as a tumor promoter in pancreatic carcinoma by regulating miR-383-5p/SOX11. Oncol Lett 2021;21:255. [PMID: 33664819 DOI: 10.3892/ol.2021.12517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Akhtar-Danesh GG, Finley C, Akhtar-Danesh N. Long-term trends in the incidence and relative survival of pancreatic cancer in Canada: A population-based study. Pancreatology. 2016;16:259-265. [PMID: 26804003 DOI: 10.1016/j.pan.2015.12.180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
441 Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020;5. [PMID: 31958291 DOI: 10.1136/esmoopen-2019-000587] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
442 Werthmann PG, Kempenich R, Lang-Avérous G, Kienle GS. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. World J Gastroenterol 2019; 25(12): 1524-1530 [PMID: 30948915 DOI: 10.3748/wjg.v25.i12.1524] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
443 Yu Y, Feng X, Cang S. A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma. Cancer Manag Res 2018;10:1507-15. [PMID: 29942152 DOI: 10.2147/CMAR.S158712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
444 Ye ZM, Li LJ, Luo MB, Qing HY, Zheng JH, Zhang C, Lu YX, Tang YM. A systematic review and network meta-analysis of single nucleotide polymorphisms associated with pancreatic cancer risk. Aging (Albany NY) 2020;12:25256-74. [PMID: 33226370 DOI: 10.18632/aging.104128] [Reference Citation Analysis]
445 Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy 2018;18:51-62. [DOI: 10.1080/14737140.2018.1403319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
446 O’neill L, Reynolds S, Sheill G, Guinan E, Mockler D, Geoghegan J, Conlon K, Reynolds JV, Hussey J. Physical function in patients with resectable cancer of the pancreas and liver–a systematic review. J Cancer Surviv 2020;14:527-44. [DOI: 10.1007/s11764-020-00875-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
447 Schmocker RK, Wright MJ, Ding D, Beckman MJ, Javed AA, Cameron JL, Lafaro KJ, Burns WR, Weiss MJ, He J, Wolfgang CL, Burkhart RA. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR). Ann Surg Oncol 2021;28:3125-34. [PMID: 33051739 DOI: 10.1245/s10434-020-09201-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
448 Lu C, Yang Z, Jiang S, Yang Y, Han Y, Lv J, Li T, Chen F, Yu Y. Forkhead box O4 transcription factor in human neoplasms: Cannot afford to lose the novel suppressor. J Cell Physiol 2019;234:8647-58. [PMID: 30515801 DOI: 10.1002/jcp.27853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
449 Lu G, Shang W, Deng H, Han Z, Hu M, Liang X, Fang C, Zhu X, Fan Y, Tian J. Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. Biomaterials 2019;195:13-22. [DOI: 10.1016/j.biomaterials.2018.12.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 24.0] [Reference Citation Analysis]
450 Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Mol Cancer Ther 2015;14:1570-81. [PMID: 25934708 DOI: 10.1158/1535-7163.MCT-15-0104] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
451 Saha A, Zhao S, Chen Z, Georgiou G, Stone E, Kidane D, DiGiovanni J. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. Mol Ther 2021;29:775-87. [PMID: 33091613 DOI: 10.1016/j.ymthe.2020.10.016] [Reference Citation Analysis]
452 Zhang XM, Zhang J, Fan H, He Q, Lang R. Feasibility of portal or superior mesenteric vein resection and reconstruction by allogeneic vein for pancreatic head cancer-a case-control study. BMC Gastroenterol 2018;18:49. [PMID: 29661201 DOI: 10.1186/s12876-018-0778-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
453 Xiong X, Rao G, Roy RV, Zhang Y, Means N, Dey A, Tsaliki M, Saha S, Bhattacharyya S, Dhar Dwivedi SK, Rao CV, McCormick DJ, Dhanasekaran D, Ding K, Gillies E, Zhang M, Yang D, Bhattacharya R, Mukherjee P. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. FASEB J 2020;34:12024-39. [PMID: 32692445 DOI: 10.1096/fj.201902826RR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
454 Zhang B, Hu Q, Yu J, Wang J, Yang H, Lou J, Cai G, Huang H, Xu M, Xiao Z, Zhang Y. Heterochronous Metastases of Lung Adenocarcinoma to Pancreas and Liver: A Case Report from Pathological Perspectives. Onco Targets Ther 2021;14:4269-73. [PMID: 34326648 DOI: 10.2147/OTT.S314385] [Reference Citation Analysis]
455 Tran TB, Maker VK, Maker AV. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg 2019;229:19-27.e1. [PMID: 30742911 DOI: 10.1016/j.jamcollsurg.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
456 Xue R, Hua L, Xu W, Gao Y, Pang Y, Hao J. Derivation and Validation of the Potential Core Genes in Pancreatic Cancer for Tumor-Stroma Crosstalk. Biomed Res Int 2018;2018:4283673. [PMID: 30519576 DOI: 10.1155/2018/4283673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
457 Cao M, Zhang PB, Wu PF, Chen Q, Ge WL, Shi GD, Yin J, Cai BB, Cao SJ, Miao Y, Jiang KR. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Biomed Res Int 2021;2021:6530298. [PMID: 33748270 DOI: 10.1155/2021/6530298] [Reference Citation Analysis]
458 Wu X, Zhao Z, Bai H, Fu T, Yang C, Hu X, Liu Q, Champanhac C, Teng IT, Ye M, Tan W. DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition. Theranostics 2015;5:985-94. [PMID: 26155314 DOI: 10.7150/thno.11938] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 11.5] [Reference Citation Analysis]
459 Sun Y, Zhang T, Wang C, Jin X, Jia C, Yu S, Chen J. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS One. 2015;10:e0119783. [PMID: 25856297 DOI: 10.1371/journal.pone.0119783] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
460 Jeong KY, Lee H. Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype. World J Gastrointest Oncol 2021; 13(11): 1544-1550 [DOI: 10.4251/wjgo.v13.i11.1544] [Reference Citation Analysis]
461 Liu Z, Liu L, Sun R, Liu C. BAF45D knockdown decreases cell viability, inhibits colony formation, induces cell apoptosis and S-phase arrest in human pancreatic cancer cells. Biosci Biotechnol Biochem 2020;84:1146-52. [PMID: 32024442 DOI: 10.1080/09168451.2020.1717923] [Reference Citation Analysis]
462 Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Žakelj M, Zadnik V, Becker N, Hackert T, Mägi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2019;68:130-9. [PMID: 29158237 DOI: 10.1136/gutjnl-2017-314828] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 14.5] [Reference Citation Analysis]
463 Lin QJ, Yang F, Jin C, Fu DL. Current status and progress of pancreatic cancer in China. World J Gastroenterol 2015; 21(26): 7988-8003 [PMID: 26185370 DOI: 10.3748/wjg.v21.i26.7988] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 129] [Article Influence: 21.2] [Reference Citation Analysis]
464 Kim ST, Kim SY, Lee J, Kim K, Park SH, Park YS, Lim HY, Kang WK, Park JO. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer 2018;18:1103. [PMID: 30419860 DOI: 10.1186/s12885-018-4995-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
465 McCarroll JA, Naim S, Sharbeen G, Russia N, Lee J, Kavallaris M, Goldstein D, Phillips PA. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol 2014;5:141. [PMID: 24782785 DOI: 10.3389/fphys.2014.00141] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 8.7] [Reference Citation Analysis]
466 Zhang L, Fang Y, Xu XF, Jin DY. Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway. Mol Med Rep 2017;15:1195-203. [PMID: 28138710 DOI: 10.3892/mmr.2017.6144] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
467 Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. EIF3B promotes cancer progression in pancreatic cancer. Scand J Gastroenterol 2021;56:281-8. [PMID: 33459066 DOI: 10.1080/00365521.2020.1868566] [Reference Citation Analysis]
468 Zheng B, Peng J, Mollayup A, Bakri A, Guo L, Zheng J, Xu H. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes. Mol Med Rep 2018;17:216-24. [PMID: 29115420 DOI: 10.3892/mmr.2017.7850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
469 Durante M, Paganetti H. Nuclear physics in particle therapy: a review. Rep Prog Phys 2016;79:096702. [DOI: 10.1088/0034-4885/79/9/096702] [Cited by in Crossref: 126] [Cited by in F6Publishing: 85] [Article Influence: 25.2] [Reference Citation Analysis]
470 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015; 21(16): 4788-4801 [PMID: 25944992 DOI: 10.3748/wjg.v21.i16.4788] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
471 ASGE Standards of Practice Committee, Eloubeidi MA, Decker GA, Chandrasekhara V, Chathadi KV, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Saltzman JR, Sharaf R, Shergill AK, Cash BD, DeWitt JM. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc. 2016;83:17-28. [PMID: 26706297 DOI: 10.1016/j.gie.2015.09.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
472 Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, Cruceru ML, Albulescu R. Cancer stem cells: Involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol 2014; 20(31): 10790-10801 [PMID: 25152582 DOI: 10.3748/wjg.v20.i31.10790] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
473 Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie X, Tang Z, Jiang X. Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells. Clin Transl Oncol 2015;17:314-21. [PMID: 25319722 DOI: 10.1007/s12094-014-1232-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
474 Jiang JH, Liu C, Cheng H, Lu Y, Qin Y, Xu YF, Xu J, Long J, Liu L, Ni QX. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochim Biophys Acta. 2015;1855:43-49. [PMID: 25432020 DOI: 10.1016/j.bbcan.2014.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
475 Tian G, Ye Z, Zhao Q, Jiang T. Complication incidence of EUS-guided pancreas biopsy: A systematic review and meta-analysis of 11 thousand population from 78 cohort studies. Asian J Surg 2020;43:1049-55. [PMID: 31974051 DOI: 10.1016/j.asjsur.2019.12.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Tan L, Ye X, Zhou Y, Yu M, Fu Z, Chen R, Zhuang B, Zeng B, Ye H, Gao W, Lin Q, Li Z, Zhou Q, Chen R. Macrophage migration inhibitory factor is overexpressed in pancreatic cancer tissues and impairs insulin secretion function of β-cell. J Transl Med 2014;12:92. [PMID: 24708788 DOI: 10.1186/1479-5876-12-92] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
477 Shen T, Zhou L, Shen H, Shi C, Jia S, Ding GP, Cao L. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep. 2017;7:7848. [PMID: 28798308 DOI: 10.1038/s41598-017-08479-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]